WO1988003558A1 - Eucaryotic expression system - Google Patents

Eucaryotic expression system Download PDF

Info

Publication number
WO1988003558A1
WO1988003558A1 PCT/US1987/002971 US8702971W WO8803558A1 WO 1988003558 A1 WO1988003558 A1 WO 1988003558A1 US 8702971 W US8702971 W US 8702971W WO 8803558 A1 WO8803558 A1 WO 8803558A1
Authority
WO
WIPO (PCT)
Prior art keywords
bip
grp78
cell
expression
fviii
Prior art date
Application number
PCT/US1987/002971
Other languages
French (fr)
Inventor
Randal J. Kaufman
Andrew Dorner
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to DE88900621T priority Critical patent/DE3789017D1/en
Publication of WO1988003558A1 publication Critical patent/WO1988003558A1/en
Priority to AT88900621T priority patent/ATE101195T1/en
Priority to KR1019880700824A priority patent/KR890700164A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6459Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Definitions

  • This invention relates to improvements in the expression an secretion of heterologous proteins from eucaryoti ⁇ cells.
  • the information which determines the destiny of a secrete protein is contained in its primary structure, and much of thi information may involve dictating appropriate post-translationa modification and correct conformation.
  • the steps in th exocytotic pathway of the processing and transit of membrane spanning and secretory proteins in mammalian cells have bee described (for reviews see Farquhar, Ann Rev Cell Biol, 1985 ornfeld & Kornf ld, Ann Rev Biochem, 1985) .
  • proteins destined for the cell surface ar first cotranslationally translocated into the lumen of th endoplas ic reticulum (ER) mediated by a signal sequence at o near the a ino terminus of the nascent chain (Blobel Dobberstein, J. Cell Biol, 1975; Walter et al., Cell, 1984)
  • ER endoplas ic reticulum
  • signal sequence is usuall removed and a high mannose oligosaccharide core unit i transferred to asparagine residues located in the sequence Asn-X Ser/Thr where X can be any amino acid, except perhaps proline.
  • N-linked core glycosylation occurs cotranslationally and i appears that the efficiency of glycosylation is dependent on the presentation of an appropriate conformation of the peptide chain as it enters the endoplasmic reticulum. Potential N-linked glycosylation sites may no longer be accessible after the protein has folded (Kornfeld & Kornfeld) .
  • Proteins move from the endoplasmic reticulum to the Golgi apparatus where modifications such as sulfation and processing of the high mannose oligosaccharide chain to a complex type occurs and the proteins are directed to their proper destinations (Dunp y & Rothman, Cell, 1985) .
  • Golgi has been identified as the rate limiting step in intracellular transport (Lodish et al.. Nature, 1983; Fitting &
  • hsp70 is the most abundant of these induced proteins. Proteins related to hsp70 are found in unstressed mammalian cells. There are three main members of the mammalian hsp70-like group of proteins: hsp70, hsc70, and GRP78 (Pelham, Cell, 1986) Following heat shock, synthesis of hsp70 is induced and the protein migrates to the nucleus where it is found in tight association with nucleoli. hsp70 can be released from this association by the addition of ATP in vitro.
  • hsp70 disaggregates heat damaged proteins by an ATP dependent mechanism to facilitate recovery from heat shock (Lewis & Pelham, EMBO J, 1985) .
  • hsc70 is found at high basal levels in growing cells and is only slightly heat inducible (Pelham, Cell, 1986) .
  • hsc70 has recently been identified as "uncoating ATPase", a constitively expressed enzyme that releases clathrin triskelions from coated vesicles in an ATP dependent reaction (Chappell et al. , Cell, 1986, Unge ickell, EMBO J, 1985) .
  • GRP78 was initially reported to be one of two proteins whose synthesis was induced by glucose starvation in chick fibroblasts (Shiu et al. , PNAS, 1977). Its synthesis can also be induced by inhibitors of N-linked glycosylation such as tunicamycin, glucosamine or 2-deoxygTucose (Olden et al., PNAS, 1979, Pouyssegur et al.- Cell, 1977). GRP78 is not heat inducible and its basal level is high in secreting- cells. Some work on the transcriptional activation of the GRP78 gene has been reported (Lin et al., Mol. Cell Biol., 1986; Resendez et al. , Mol.
  • BiP immunoglobulin heavy chain binding protein
  • BiP/GRP78 may associate in secreting cells wit underglycosylated or improperly folded proteins in th endoplasmic reticulum and help clear them in analogy to the hypo thesized role of hsp70 in the nucleus (Pelham, Cell, 1986) . Suc a function is consistent with the induction of increased level of GRP78 synthesis under conditions which disrupt N-linke glycosylation. Recent studies on abberant proteins which fail t transit out- of the ER have been interpreted to show that Bi binds to them in the ER although the identity of grp78 and BiP was disputed (Gething et al..
  • BiP/GRP78 may also associate with partial ⁇ ly assembled proteins and retain them in the ER until assembly and processing is complete as is the case for the processing of immunoglobulin heavy chain (Bole et al., J Cell Biol, 1986).
  • This invention provides an anti-sense expression vector capable of directing the transcription of mRNA complementary to mRNA encoding- GRP78 protein (BiP) .
  • the anti-sense expression vector thus directs the transcription of "anti-sense" mRNA which is capable of hybridizing to part or all of the endogenous GRP78/BiP-encoding mRNA of a eucaryotic host cell, thereby preventing or decreasing, preferably significantly decreasing, the level of translation of GRP78/BiP mRNA and thus the level of BiP/GRP78 protein in a host cell transformed or transfected with the anti-sense expression vector of this invention.
  • the anti- sense expression Vector comprises a DNA sequence encoding part or all of a GRP78 protein or an expression control sequence thereof, operatively linked in reverse orientation to an expression control sequence permitting transcription of the anti-sense mRNA.
  • the expression control sequence comprises a promoter and optionally an enhancer to which the promoter is responsive, as well as other optional genetic elements, all as are well known in the art.
  • the host cell's BiP-encoding mRNA or DNA may contain fewer bases or base pairs than the host cell's BiP-encoding mRNA or DNA, and/or (ii) may be mutagenized or otherwise contain a number of substituted bases or base pai for naturally occurring ones, so long as the anti-sense mR hybridizes to a sufficient portion of the host cell's GRP78/B mRNA to prevent or decrease, preferably significantly, the lev of GRP78/BiP mRNA translation. Prevention or reduction o translation can be conveniently measured by methods describ hereinafter.
  • the anti-sense expression vector may also contai one or more a plifiable markers permitting the amplification o gene copy number by conventional techniques, one or mor selectable markers, and other elements heretofore generally know in the art to be useful in expression vectors, as disclosed i greater detail below.
  • Suitable anti-sense expression vectors may be synthesized by techniques wel known in the art.
  • the components of the vectors such a bacterial replicons, selection genes, amplifiable markers enhancers, promoters, and the like may be obtained from natura sources or synthesized by known procedures. See Kaufman et al. 1982, J.Mol. Biol. ,159;601-621; Kaufman, 1985, Proc. Natl. Acad Sci. 8.: 689-693.
  • the DNA sequence encoding the BiP anti-sens mRNA may be obtained or synthesized as described hereinafter.
  • This invention further encompasses an improved eucaryotic hos cell for expressing a heterologous protein such as Factor VIII; t-PA; von Willebrand Factor (VWF) ; erythropoietin; lymphokine such as GM-CSF, other CSFs, 11-2, 11-3; etc., or analogs thereof.
  • a heterologous protein such as Factor VIII; t-PA; von Willebrand Factor (VWF) ; erythropoietin; lymphokine such as GM-CSF, other CSFs, 11-2, 11-3; etc., or analogs thereof.
  • Factor VIII analogs are described, e.g. i International Applications PCT/US87/01299 and PCT/US87/00033 an in U.S. Serial No. 068,865 (filed July 2, 1987), the contents of which are hereby incorporated by reference.
  • t-PA analogs are described e.g. in U.S. Serial Nos.
  • the improved host cell of this invention comprises a host cell transformed or transfected with an anti-sense expression vector of this invention, or the progeny thereof.
  • the improved host cell may be a bacterial, yeast, fungal, plant, insect or mammalian cell or cell line, and is preferably a mammalian cell or cell line.
  • Established cell lines including transformed cell lines, are suitable as hosts.
  • Normal diploid cells cell strains derived from in vitro culture of primary tissue, as well as primary explants (including relatively undifferentiated cells such as hematopoetic stem cells) are also suitable.
  • Candidate cells need not be genotypically deficient in a selection gene so long as the selection gene is dominantly acting.
  • the host cells preferably will be established mammalian cell lines.
  • CHO Choinese Hamster Ovary
  • vector DNA may include all or part of the bovine papilloma virus genome (Lusky et al., 1984, Cell 2_6:391-401) and be carried in cell lines such as C127 mouse cells as a stable episomal element.
  • Other usable mammalian cell lines include HeLa, COS-1 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HAK hamster cell lines and the like.
  • the improved host cell, or the progeny thereof may further be transformed or transfected with one or more expression vectors capable of directing the expression of the desired protein. This may be accomplished directly, i.e., by transforming or transfecting the host cell or its progeny with an expression vector encoding the desired protein, prior or subsequent to transformation or transfection of the host cell with the anti- sense vector of this invention. Alternatively, this may be accomplished "indirectly", i.e., by fusion of cells transformed or transfected with the anti-sense vector or their progeny wi cells transformed or transfected with the vector encoding t desired protein.
  • Suitable vectors for the expression of a lar number of diverse proteins are known in the art and are eith publicly available or may be synthesized by purely convention techniques.
  • Vectors containing DNA encoding the followin proteins have been deposited with the American Typ Culture Collection (ATCC) of Rockville, MD: Factor VIII (pSP64 VIII, ATCC No. 39812); a Factor VIII analog,"LA", lacking 58 amino acids (pDGR-2, ATCC No. 53100) ;t-PA and analogs thereo (see e.g. International Application WO 87/04722, published 1 August 1987); VWF (pMT2-VWF, ATCC No.
  • EPO pRKl-4, ATC No.39940
  • pdBPVMMTneo 342-12 BPV-type vector, ATCC No.37224
  • GM-CSF pCSF-1, ATCC No. 39754
  • the method comprises culturing eucaryotic host cell transformed with a vector capable o directing the expression of the heterologous protein, or th pregeny thereof, the host cell or its progeny being additionall transformed or transfected with (a) an anti-sense GRP78/Bi vector of this invention; (b) a vector, preferably amplified t multi-copy number, containing a DNA sequence substantially th same as the following heterologous DNA sequence, or a portio thereof so long as it is capable of reducing or preventing Bi induction under conditions which otherwise typically induce Bi expression:
  • the DNA insert in the vector in (b) is believed to contain a regulatory element required for induction of transcription of the GRP78 gene, perhaps by binding with an endogenous trans-acting transcriptional regulatory factor which is produced by the host cell in response to BiP-inducing conditions. It is believed that the factor normally binds to an endogenous transcription control element linked to the endogenous BiP gene and thereby causes increased BiP mRNA levels under BiP-inducing conditions.
  • the presence of the vector in (b) preferably amplified to multi ⁇ copy number, is believed to compete with the endogenous transcription control sequence for binding to the transcription initiation factor, and thus to block the BiP induction pathway.
  • Reduced levels of BiP we mean levels of BiP below, preferably at least 20% below, more preferably least 50% below, and even more preferably at least 75% below, t level of BiP in CHO cells under BiP-inducing conditions such glucose deprivation. Factor VIII overexpression, treatment wi tunicamycin or A23187, etc.
  • BiP levels may be convenientl measured by standard procedures such as immunological assa using antibodies directed to BiP or to BiP-heterologous protei complex. Alternatively, BiP levels may be measured indirectly b measuring endogenous levels of RNA encoding BiP using standar procedures such as Northern or Southern blotting.
  • This method is believed to produce higher recoverable yields o heterologous proteins, which may otherwise be intractably boun within the ER, owing to decreased ER levels of BiP resulting fro decreased levels of translation of the host cell's endogenou BiP-encoding mRNA, in the case of (a) ; decreased levels o induction of the host cell's endogenous BiP gene, in the case o (b) ; and decreased levels of BiP induction and translation, i the case of (c) .
  • Other methods for achieving reduced endogenou BiP levels which will occur to those skilled in this art ar expected to be operative to a greater or lesser extent than th specific methods disclosed herein, and should thus be viewed a equivalent methods.
  • stable transformants prepare for use in the improved method or their progeny are screened fo decreased expression of BiP and/or expression of the heterologou protein by standard immunological or enzymatic assays. Th presence of anti-sense mRNA or mRNA encoding the heterologou protein and/or DNA encoding the heterologous protein or a DN sequence present in the vectors of (a) and/or (b) , above, may be detected by standard procedures such as Northern or Southern blotting respectively. Transient expression of the anti-sense vector and/or the DNA encoding the heterologous protein during the several days after introduction of the respective vector(s) into COS-1 monkey cells is measured without selection by activity or immunological assay of the proteins in the culture medium.
  • the protein so produced may be recovered, purified, and/or characterized, all by known methods.
  • This invention also encompasses a "sense" GRP78/BiP expression vector which comprises a DNA sequence encoding GRP78/BiP operatively linked to an expression control sequence. Construction of an exemplary GRP78/BiP expression vector is described in detail below, but it should be understood that other BiP expression vectors may be readily prepared by purely conventional techniques using a GRP78/BiP-encoding DNA sequence and readily available or synthesizable components, as is true for other exemplary vectors of this invention described hereinafter.
  • This invention also encompasses a eucaryotic host cell, as described above, but which is transformed or transfected with a GRP78/BiP expression vector.
  • a eucaryotic host cell as described above, but which is transformed or transfected with a GRP78/BiP expression vector.
  • Such an engineered host cell or its progeny may be further transformed with an expression vector capable of directing the transcription of a heterologous protein, also as described above.
  • the resultant cell or its progeny may then be cultured in an improved method for producing the heterologous protein, wherein improperly glycosylated or folded heterologous protein is not secreted into the culture medium, but is instead retained within the host cell by virtue of association with intracellular BiP.
  • FVIII human factor VIII
  • tPA human tissue plasminogen activator
  • vWF human von Willebrand Factor
  • FVIII is synthesized as a single chai precursor of about 250 kd and subsequently processed to a "hea chain" of about 200 kd and a "light chain” doublet of about 8 kd.
  • FVIII has a plethora of potential N-linked glycosylatio sites.
  • tPA has a molecula weight of about 68,000 kd and contains four potential N-linke glycosylation sites of which three are typically occupied (Poh et al., Biochem, 1984).
  • vWF is a large glycoprotein synthesize as an approximately 260,000 kd precursor which forms di ers i the endoplasmic reticulum and is subsequently processed in Golg and post-Golgi compartments to approximately 100,000 and 220,00 kd forms (Bonthron et al.. Nature, 1986). These processed form undergo interdimer disulfide bond formation to form hig molecular weight multimers (Wagner & Marder, J. Cell Biol. 1984) .
  • LA is a deleted form of FVIII which has only 7 potential N-linked sites compared to 25 en wt FVIII.
  • Bi Single chain LA appears as a doublet of approximately 150 kd. with wt FVIII no 80kd forms are observed to be complexed wi BiP.
  • BiP protein induced by tunicamycin treatment which comigrates with the protein identified as BiP by immunoprecipitation with the anti-BiP monoclonal.
  • the molecular weight of BiP does not change following tunicamycin treatment indicating it is not normally N- 1inked glycosylated.
  • vWF complex glycoprotein
  • the precursor form of vWF has 17 N-linked glycosylation sites spread along the molecule.
  • the 260Kda VWF precursor protein is observed inside CHO cells. Roughly 10% of this protein is found complexed with BiP.
  • VWF is efficiently and rapidly secreted such that at the 4h chase point approximately 90% of the 260kda precursor is gone from the cell extract and the conditioned medium contains the processed forms of 275 and 220 kD.
  • T-PA has potential N-linked glycosylation sites of which 3 are utilized t-PA appears as a doublet or roughly 68 kD due to variability i the utilization of one of the three glycosylation sites.
  • t-PA3 is genetically engineered mutant in which the three normall utilized N-linked glycosylation sites have been abolished by As to Gin codon changes in the canonical recognition site sequences See International Application No. PCT/US87/00257.
  • t-PAwt Glycosylated unmodified unmodified t-PA (i.e. wild type, "t-PAwt") wa efficiently processed and secreted in a high producing CHO cel line, t-PAwt cell line.
  • t-PAwt exhibite a slight association with BiP.
  • t-PAwt During the lh and 3h chas periods most of the t-PAwt had been secreted into the medium an little if any association with BiP could be detected intracellularly at these times.
  • BiP Glycosylated unmodified t-PA
  • t-PA3x-13 produces roughly 200-fold higher levels of t-PA3x that t-PA3x-4.
  • t-PA3x displays a significant association with BiP in sharp contrast to that observed for the t-PA3x-4 line.
  • the amount of t-PA3x associated with BiP decreases slightly between the pulse time point and the lh chase point.
  • the amount of t-PA3x found in a complex with BiP remains the same between the lh and 3h chase points.
  • t PA Unglycosylated t-PA appears as doublet in these experiments.
  • t PA is synthesized with a 12-15 amino acid long propeptide at the amino terminus of the protein (Pennica et al. Nature 1983) .
  • the higher molecular weight band represents the uncleaved pro-t-PA precursor form while the lower band represents the mature form which has been processed to remove the amino terminal propeptide.
  • propeptide cleavage occurs in Golgi and post-Golgi compartments and BiP has been localized to the endoplasmic reticulum, only the pro-t-PA precursor form should be present in the same compartment as BiP. Consistent with this interpretations is the observation that only the higher molecular weight species of the doublet is found associated with BiP while only the lower molecular weight species is secreted.
  • a cDNA coding sequence for Chinese hamster GRP78 was placed in the expression vector pMT2 which is a derivative of p91023b and this expression vector (pMTGRP78) was ⁇ otransfected into COS cells with wt FVIII (pMT2VIII) or LA (pMT2LA) expression vectors to examine the consequences of overexpression of GRP78 on FVIII secretion.
  • the transient expression of FVIII was monitored by assaying the conditioned medium for FVIII activity. Expression of GRP78 was detected by immunoprecipitation with the anti-BiP monoclonal.
  • pMT2 may be obtained from pMT2-vWF (ATCC No. 67122) as described in detail below.
  • Coexpression of GRP78 and FVIII in COS cells consistently resulted in a 6-10 fold reduction in the levels of FVIII activity in the conditioned medium (Table I, below) .
  • the effect of two different replicating vectors in the same cell is a decrease in the expression of both vectors.
  • FVIII or LA vectors were always cotransfected with pCSF-1.
  • pCSF-1 is an expression vector for GM-CSF which carries similar replication and transcription elements as pMT2 (Wong et al Science 1985) .Coexpression of LA and GRP78 in COS cells resulted in a 2-3 fold reduction the levels of LA activity in the medium.
  • the degree of decrease of activity of LA and wt FVIII a consistent with the degree of association of FVIII and LA wi BiP in CHO cells.
  • the heavily glycosylated wt FVIII is mo affected by GRP78 expression than LA in the transient COS syst and also displays a stronger association with BiP in stable C cell lines. This data indicates that high levels of GRP78 c interfere with the secretion of FVIII and is suggestive that B and GRP78 are functionally and structurally similar.
  • GRP78 cDNA used is a matter of choice.
  • a rat cDNA clone may be obtaine also as described (Munro & Pelham, Cell, 1986) . Sequenc analysis has shown that both of these clones encode the sa protein identified as GRP78. At the amino acid level the rat an hamster proteins are 99.4% homologous.
  • Cloning of a functiona GRP78 cDNA may be effected using one or more oligonucleotide derived from the published sequence of GRP78 and purel conventional techniques as described by Lee et al. or Munro Pelham, supra.
  • a cloned rat cDNA may be obtaine from Dr. Pelham, MRC Laboratory of Molecular Biology, Hills Road Cambridge CB2 2QH, England.
  • a DNA sequenc encoding any desired GRP78 may be synthesized, e.g. usin overlapping oligonucleotides which together span the desire sequence.
  • Chinese hamster GRP78 cDNA was placed into a mammalian expressio vector pMT2.
  • This vector is a derivative of p91023B and may be obtained by EcoRI digestion of pMT2-vWF, which has been deposited with the American Type Culture Collection under ATCC No. 67122. EcoRI digestion excises the cDNA insert present in pMT2-vWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB101 or DH5 to ampicillin resistance. Plasmid pMT2 DNA can then be prepared by conventional methods. The 1962 nucleotide open reading frame encoding hamster GRP78 was excised by Pstl and EcoRV digestion. The vector was prepared by EcoRI digestion, the EcoRI ends were filled in using Klenow fragment and then the vector was digested with Pstl.
  • the fragment from the hamster clone was ligated into the prepared pMT2 vector, although as indicated previously, other eucaryotic expression vectors may also be used.
  • the resultant plasmid pMTGRP78 contains the adenovirus-VA genes, SV40 replication origin including enhancer, adenovirus major late promoter (MLP) including tripartite leader and 5' donor splice site, 3' splice acceptor site, GRP78 cDNA insert in proper orientation relative to the MLP for expression of GRP78, DHFR cDNA insert, SV40 early polyadenylation site and pBR322 sequences.
  • MLP adenovirus major late promoter
  • pMTGRP78 was used to cotransfect COS-1 cells along with the FVIII expression vectors pMT2VIII or pMT2LA (Toole et al., PNAS, 1986) using the DEAE dextran procedure (Kaufman, PNAS, 1985). Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity as described (Toole et al., Nature, 1984). The results of these experiments are summarized in Table I. Previous work has shown that cotransfection of two different expression vectors reduces the level of expression compared to transfection of a single vector.
  • pCSF-1 a previously described vector which expresses GM-CSF (Wong et al Science 1985) .
  • pCSF-1 is available from the American Type Culture Collection in E. coli MC1061 as ATCC 39754.
  • Chinese hamster GRP78 cDNA was placed into pMT2 in the opposit orientation from that in the above-described expression vector.
  • the 1962 nucleotide open reading frame was excised as follows.
  • the hamster GRP78 clone was digested with EcoRv and a Pstl linke was ligated to the blunt EcoRV end.
  • the DNA was then cut wit Pstl to excise the 1962 bp open reading frame.
  • the vector pMT2 was prepared by digestion with Pstl. The fragment from th hamster was ligated into the Pstl site of pMT2.
  • the resultant plasmid pMT B2 was analyzed by extensive restriction digest mapping, and it was determined that the vector carries the GRP78 cDNA sequences such that the 3' end of the GRP78 cDNA was closest to the adenovirus major late promoter.
  • transcripts expressed from the adenovirus major late promoter contain sequence which is the complement of the GRP78 coding sequence.
  • Such a RNA is commonly referred to as an antisense RNA. It has been reported that antisense RNA can interact intracellularly with its complementary sense mRNA and block the synthesis of the encoded protein (Kim and Wold, Cell, 1985) .
  • pMT2 ⁇ B2 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md 20852 (USA) under accession number ATCC 40387. It should be noted that the cDNA insert may be excised with Pstl digestion and the excised cDNA re-inserted in either orientation into an alternative expression vector, using synthetic linkers, if necessary. The excised cDNA may also be used as a hybridization probe to identify and clone other DNA molecules encoding BiP proteins or (by probing a genomic library) containing transcriptional regulatory nucleotide sequences for BiP proteins, by conventional methods.
  • pMT ⁇ B2 was used to cotransfect COS-1 cells along with the FVIII expression vector pMT2VIII using the DEAE dextran procedure.
  • Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity.
  • Table II The results of such an experiment are summarized in Table II.
  • coexpression of FVIII and antisense GRP78 sequences resulted in a 50% increase in FVIII activity in the conditioned medium compared to coexpression of FVIII and GM- CSF. This data indicates that the introduction of an antisense vector to decrease the intracellular level of GRP78 can result in increased levels of FVIII secretion.
  • Chromocrenic Activity milliunits/ml
  • T plasmids indicated were cotransfected into COS-1 cells and the conditioned medium removed for assay by the Kabi Coatest F(VIII) : C method.
  • Chromoqenic Activity (milliunits/ml ) pMTVIII/pCSF-1 90 pMTVIII/pMT ⁇ B2 135
  • the plasmids indicated were cotransfected into COS-1 cells an conditioned medium removed for an assay by the Kabi Coates F (VIII) : C method.
  • CHO cell lines which are DHFR deficient, CHO" (DUKX-Bll) , were grown in an alpha medium supplemented with lOug/ml each of thymidine, deoxyadenosine and adenosine.
  • Cells were cotransfected with pMT ⁇ B2 (20 ⁇ g) and pSV2Neo (2 g) (ATCC No. 37149) by the calcium phosphate coprecipitation procedure (Kaufman et al JMB 1982) .
  • pSV2Neo codes for resistance to the antibiotic G418 (P. Southern & Berg P. 1982 J. Mol. Appl. Genet. 1 327-341).
  • pMT ⁇ B2 contains an intact DHFR coding region in the 3' region of the antisense GRP78 transcript.
  • G418 resistant transformants can be subsequently selected for DHFR expression from this mRNA.
  • Growth in alpha media lacking nucleosides with 10% dialyzed fetal calf serum resulted in DHFR + colonies.
  • Five colonies were pooled to produce the A6B line. This line was then amplified by selection for growth in the presence of the folic acid analogue methotrexate at a concentration of .02uM.
  • the BiP/GRP78 level in A6B was compared to CHO DUKX by immunoprecipitation of radiolabeled cell extracts with anti-BiP monoclonal and analysis by SDS PAGE. Additionally, the level of BiP/GRP78 was measured by Western analysis using anti-BiP monoclonal antibody. A6B showed reduced levels of BiP/GRP78 compared to the original CHO line. In addition the level of antisense GRP78 RNA derived from pMT B2 in these cells was determined by Northern analysis. 2) Fusion of H9 with BiP/GRP78 reduced cell line
  • the A6B cell line was fused with a FVIII producing cell l ine , H9 , by standard polyethylene glycol procedure following treatment of the A6B cells with DEPC to render them nonviable (WE Wright , Chap 5 , The S election of Heterokaryons and Cell Hybrids Using the Biochemical Inhibitors Iodoaceta ide and Diethylpyrocarbonate in Techniques in Somatic Cell Genetics, Ed. JW Shay, Plenum Press) . Two days following cell fusion the cells were plated in luM methetrexate and lmg/ml G418.
  • H9 grows in luM methetrexate and G4 ⁇ 8 selects for the chromosome containing the antisense GRP78 sequences derived from A6B cells . After eleven days of growth twenty-two colonies were pooled to produce the cell line designated H9XA6B-9. Determination to the level of FVIII procoagulant activity secreted into the conditioned medium by H9xA6B-9 showed that this cell line yielded two-fold greater activity than the original H9 line.
  • CHO DUKX cells as above were cotransfected with pMT B2 (20 ug) and pSV2AdA (2 ug) by the calcium phosphate coprecipitation procedure.
  • pSV2AdA codes for adenosine deaminase and allows for cell growth in the presence of cytotoxic concentrations of adenosine and the drug deoxycoformycin(dCF) .
  • Forty-eight hours post-transf ection the cells were plated in alpha medium supplemented with deoxyadenos ine , thymidine , uridine (U) , alanosine (A) , adenosine (A) , and .
  • the C6B line growing in 1 uM dCF was fused with a tPA3x producing cell line tPA3x-9.
  • Two days following cell fusion cells were plated into alpha medium containing AAU, 1 uM dCF and 0.02 uM methotrexate.
  • tPA3x-9 grows in 0.02 methotrexate and dCF selects for the chromosome containing antisense GRP78 sequences. After 11 days of growth 9 colonies were pooled to produce the laE line. Determination of the level of tPA activity secreted into the conditioned medium showed that this line yielded 2-5 fold greater activity than the original tPA3x-9 line.
  • a DNA sequence containing the BiP/GRP78 regulatory element was removed from pUC291R (Lin et al., Mol. Cell Biol., 1986) by digestion of the plasmid with Sma I and Hindi.
  • the DNA fragment so obtained contains the 291 (Smal/Stul) nucleotide sequence bearing the regulatory element required for induction of the rat GRP78 gene.
  • the 360 nucleotide sequence shown above on page 7, or a portion thereof may be synthesized by purely conventional methods, e.g. through the synthesis of overlapping oligonucleotides which together span the desired sequence.
  • GRP78 regulatory sequence derived from other species should also be usable in this invention, whether isolated from a genomic DNA library or chemically synthesized. It is believed that a trans-acting factor or factors may bind to regulatory sequence(s) within the DNA fragment so obtained and thus mediate induction of GRP78 transcription. It has been reported that such DNA fragments can compete for the hypothesized trans-acting factor(s) n vivo (Lin et al., Mol. Cell Biol., 1986).
  • Operability of the regulatory fragment to be used may be conveniently assayed by methods such as described by Lin et al., Mol. Cell Biol., 1986.
  • the regulatory DNA sequence to be used is then inserted into a conventional expression vector for use in eucaryotic cells, preferably mammalian cells, either directly or with synthetic linkers if desired.
  • the regulatory sequence may be inserted with synthetic EcoRI linkers into the EcoRI site in expression vector, pMT2.
  • pMT2 may be obtained by EcoRI digestion of pMT2-VWF, which has been deposited (29 May 1986) with the American Type
  • Plasmid pMT2 DNA can be prepared by conventional methods. Of course, other expression vectors known in the art may be used in place of pMT2, using appropriate linkers as desired or necessary.
  • the expression vector containing the regulatory sequence is then cotransfected or cotransformed into the desired host cell with one or more selectable, amplifiable markers, as is known in the art, and gene copy number of the heterologous DNA may be amplified as desired using conventional methods.
  • the presence of multiple copies of the regulatory sequence in the cellular genome should compete with the endogenous GRP78 expression control sequences for binding wit the trans-acting factor(s) following induction by conditions such as blockage of N- linked glycosylation, over-expression of FVIII : c or analogs thereof , etc.
  • Such competition for trans-acting factors has been reported for a metalothionein I gene (Seguin et al .
  • the ratio of induced BiP transcription levels to normal BiP transcription levels is less than about 20 , more preferably less than about 10 , even more preferably less than about 5 , and especially preferably less than about 1.
  • Transformants or transf ectants , or the progeny thereof, which contain the vector-borne regulatory sequence may additionally be transformed or trans fected with an expression vector capable of directing the synthesis of a desired heterologous protein.
  • they may be fus ed with other c el ls which had been previously transformed or transfected with an expression vector capable of directing the synthesis of the des ired heterologous protein .
  • Suitable vectors capable of directing the synthesis of heterologous proteins are known in the art and discussed previously.
  • wt FVIII is associated with BiP and most of the FVIII which is never secreted remains associated with BiP. 20 out of 25 N-linked glycosylation sites are clustered in middle third of the FVIII protein.
  • LA a deleted form of FVIII which has 18 of 20 clustered glycosylation sites removed, is more efficiently secreted than wt FVIII exhibits a transient association with BiP.
  • VWF a complex gly ⁇ oprotein which is efficiently secreted by CHO cells, exhibits only a transient association with BiP.
  • the 17 glycosylation sites on VWF are spaced along the molecule rather than clustered as on wt FVIII.
  • tPA exhibits only a slight transient association with BiP.
  • tunicamycin results in the intracellular retention of some of the unglycosylated molecules in a complex with BiP.
  • tPA3x an engineered mutant of t-PA which has had three potential N-linked glycosylation sites abolished by replacement of Asn with Gin exhibits only a slight association with BiP at low expression levels. However, at high expression levels a fraction of the unprocessed protein displays a stable association with BiP and is apparently not secreted effeciently. This behavior is similar th that observed for wt t-PA when glycosylation is inhibited.
  • Intracellular retention of unglycosylated tPA in a complex with BiP is dependent on expression level.
  • tPA3x at low expression levels is not associated with BiP and is effeciently secreted.
  • tPA3x is associated with BiP.
  • This intracellular retention is similar to that observed for the high producer wt tPA cell line when N-linked glycosylation is inhibited.
  • the eff ect of inhibition of N-linked glycosylation is less pronounced than in higher-producing cells . This suggests that unglycosylated tPA may aggregate when present at high concentrations in the ER leading to its association with BiP.
  • BiP may associate with improperly glycosylated or folded proteins in the endoplasmic reticulum and prevent the ir secretion. BiP probably functions to clear aggregated proteins from the endoplasmic reticulum in an analogous function to hsp70 in heat shocked nucleoli.
  • the problem of protein aggregation or insolubility in the ER may be exacerbated by the high expression levels now attainable by re ⁇ ombinant DNA expressioin techniques and for some glyc ⁇ proteins such as FVIII aggregation and consequent association with BiP may prove a barrier to high level secretion.
  • the 20 clustered glycosylation sites in the middle of wt FVIII may be inefficiently glycosylated resulting in aggregation of improperly folded molecules and stable association with BiP . It is also possible that this heavily glycosylated domain assumes a conformation which BiP recognizes as aberrant even if N-linked glycosylation is appropriate. In this situation secretion competent molecules may be trapped in a complex with BiP and reduced levels of BiP may result in higher levels of secretion.
  • Glucose deprivation accounts for the induction of two transf omat ion- sensitive membrane proteins in Rous sarcoma virus -trans formed chick embryo fibfoblasts. Proc. atl. Acad. Sci. USA 74:3840-3844.
  • Uncoating ATPase is a member of the 70- kD family of stress proteins. Cell 45:3-13.
  • Tissue plasminogen activator peptide analysis confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 23,3701-3707.

Abstract

Vectors, improved host cells and improved methods for producing a heterologous protein by culturing an improved eucaryotic host cell of this invention transformed or transfected with a vector capable of directing the expression of the heterologous protein. An expression vector containing DNA encoding an anti-sense RNA to GRP78 protein-encoding mRNA is used to increase levels of heterologous proteins.

Description

EUCARYOTIC EXPRESSION SYSTEM
Background of the Invention
This invention relates to improvements in the expression an secretion of heterologous proteins from eucaryotiσ cells.
The information which determines the destiny of a secrete protein is contained in its primary structure, and much of thi information may involve dictating appropriate post-translationa modification and correct conformation. The steps in th exocytotic pathway of the processing and transit of membrane spanning and secretory proteins in mammalian cells have bee described (for reviews see Farquhar, Ann Rev Cell Biol, 1985 ornfeld & Kornf ld, Ann Rev Biochem, 1985) . A large body o work has shown that proteins destined for the cell surface ar first cotranslationally translocated into the lumen of th endoplas ic reticulum (ER) mediated by a signal sequence at o near the a ino terminus of the nascent chain (Blobel Dobberstein, J. Cell Biol, 1975; Walter et al., Cell, 1984) Inside the endoplasmic reticulum the signal sequence is usuall removed and a high mannose oligosaccharide core unit i transferred to asparagine residues located in the sequence Asn-X Ser/Thr where X can be any amino acid, except perhaps proline. This N-linked core glycosylation occurs cotranslationally and i appears that the efficiency of glycosylation is dependent on the presentation of an appropriate conformation of the peptide chain as it enters the endoplasmic reticulum. Potential N-linked glycosylation sites may no longer be accessible after the protein has folded (Kornfeld & Kornfeld) .
Proteins move from the endoplasmic reticulum to the Golgi apparatus where modifications such as sulfation and processing of the high mannose oligosaccharide chain to a complex type occurs and the proteins are directed to their proper destinations (Dunp y & Rothman, Cell, 1985) . The movement from the ER to the
Golgi has been identified as the rate limiting step in intracellular transport (Lodish et al.. Nature, 1983; Fitting &
Kabat, JBC, 1982, and J. Cell Biol, 1985). Few proteins resident in the ER have been extensively studied for their interaction with secretory proteins transiting that compartment.
Environmental stresses such as heat shock induce the synthesis in prokaryotic and eukaryotic cells of a set of highly conserved heat shock proteins. (Schlesinger, J. Cell Biol, 1986). hsp70 is the most abundant of these induced proteins. Proteins related to hsp70 are found in unstressed mammalian cells. There are three main members of the mammalian hsp70-like group of proteins: hsp70, hsc70, and GRP78 (Pelham, Cell, 1986) Following heat shock, synthesis of hsp70 is induced and the protein migrates to the nucleus where it is found in tight association with nucleoli. hsp70 can be released from this association by the addition of ATP in vitro. It has been hypothesized that hsp70 disaggregates heat damaged proteins by an ATP dependent mechanism to facilitate recovery from heat shock (Lewis & Pelham, EMBO J, 1985) . hsc70 is found at high basal levels in growing cells and is only slightly heat inducible (Pelham, Cell, 1986) . hsc70 has recently been identified as "uncoating ATPase", a constitively expressed enzyme that releases clathrin triskelions from coated vesicles in an ATP dependent reaction (Chappell et al. , Cell, 1986, Unge ickell, EMBO J, 1985) .
GRP78 was initially reported to be one of two proteins whose synthesis was induced by glucose starvation in chick fibroblasts (Shiu et al. , PNAS, 1977). Its synthesis can also be induced by inhibitors of N-linked glycosylation such as tunicamycin, glucosamine or 2-deoxygTucose (Olden et al., PNAS, 1979, Pouyssegur et al.- Cell, 1977). GRP78 is not heat inducible and its basal level is high in secreting- cells. Some work on the transcriptional activation of the GRP78 gene has been reported (Lin et al., Mol. Cell Biol., 1986; Resendez et al. , Mol. Ce Biol., 1985; Chang et al. , Proc. Nat ' 1. Acad. Sci., 1987) Recently it has been shown that GRP78 is similar if not identica to immunoglobulin heavy chain binding protein (BiP) (Munro an Pelham, Cell, 1986). GRP78 is therefore also referred t hereinafter as BiP/GRP78 or simply, BiP. BiP was first describe for its association with immunoglobulin heavy chains in pre- cells (Haas and Wable, Nature, 1983) . BiP transiently complexe with immunoglobulin heavy chain in the endoplasmic reticulum o secreting hybridomas. When assembly with light chains occurs Bi dissociates from the complex. In the absence of light chains Bi remains associated with heavy chains and this complex is no transported from the endoplasmic reticulum to the Golgi apparatu (Bole et al. , J. Cell Biol., 1986) . These subcellula fractionation studies showed that BiP is predominantly localize to the endoplasmic reticulum. The heavy chain-BiP complex ca be dissociated in the presence of ATP suggesting a functiona analogy with the hsp70 complex in heat shocked nucleoli. (Munro Pelham, Cell, 1986) .
We believe that BiP/GRP78 may associate in secreting cells wit underglycosylated or improperly folded proteins in th endoplasmic reticulum and help clear them in analogy to the hypo thesized role of hsp70 in the nucleus (Pelham, Cell, 1986) . Suc a function is consistent with the induction of increased level of GRP78 synthesis under conditions which disrupt N-linke glycosylation. Recent studies on abberant proteins which fail t transit out- of the ER have been interpreted to show that Bi binds to them in the ER although the identity of grp78 and BiP was disputed (Gething et al.. Cell, 1986; Sharma et al., EMBO J, 1985) and the extent and degree of such binding was not specif¬ ically characterized. BiP/GRP78 may also associate with partial¬ ly assembled proteins and retain them in the ER until assembly and processing is complete as is the case for the processing of immunoglobulin heavy chain (Bole et al., J Cell Biol, 1986). Independent of the research on BiP mentioned above, we have conducted extensive research on the production of glycoproteins, including Factor VIII, in genetically engineered host cells. In the course of this research we have surprisingly found that a significant proportion of Factor VIII and analogs thereof (also referred to hereinafter, simply as "Factor VIII") and analogs of tPA produced in vitro, e.g. in CHO cells, is not secreted into the cell culture medium. We have now surprisingly found that secretion levels for Factor VIII and other proteins can be decreased by providing higher intracellular levels of BiP and can be increased by reducing the intracellular BiP level.
Summary of the Invention
This invention provides an anti-sense expression vector capable of directing the transcription of mRNA complementary to mRNA encoding- GRP78 protein (BiP) . The anti-sense expression vector thus directs the transcription of "anti-sense" mRNA which is capable of hybridizing to part or all of the endogenous GRP78/BiP-encoding mRNA of a eucaryotic host cell, thereby preventing or decreasing, preferably significantly decreasing, the level of translation of GRP78/BiP mRNA and thus the level of BiP/GRP78 protein in a host cell transformed or transfected with the anti-sense expression vector of this invention. The anti- sense expression Vector comprises a DNA sequence encoding part or all of a GRP78 protein or an expression control sequence thereof, operatively linked in reverse orientation to an expression control sequence permitting transcription of the anti-sense mRNA. The expression control sequence comprises a promoter and optionally an enhancer to which the promoter is responsive, as well as other optional genetic elements, all as are well known in the art. The anti-sense mRNA, and thus the corresponding DNA in the anti-sense expression vector, (i) need not be full-length, i.e. may contain fewer bases or base pairs than the host cell's BiP-encoding mRNA or DNA, and/or (ii) may be mutagenized or otherwise contain a number of substituted bases or base pai for naturally occurring ones, so long as the anti-sense mR hybridizes to a sufficient portion of the host cell's GRP78/B mRNA to prevent or decrease, preferably significantly, the lev of GRP78/BiP mRNA translation. Prevention or reduction o translation can be conveniently measured by methods describ hereinafter. The anti-sense expression vector may also contai one or more a plifiable markers permitting the amplification o gene copy number by conventional techniques, one or mor selectable markers, and other elements heretofore generally know in the art to be useful in expression vectors, as disclosed i greater detail below.
Suitable anti-sense expression vectors, as are described i greater detail herein, may be synthesized by techniques wel known in the art. The components of the vectors such a bacterial replicons, selection genes, amplifiable markers enhancers, promoters, and the like may be obtained from natura sources or synthesized by known procedures. See Kaufman et al. 1982, J.Mol. Biol. ,159;601-621; Kaufman, 1985, Proc. Natl. Acad Sci. 8.: 689-693. The DNA sequence encoding the BiP anti-sens mRNA may be obtained or synthesized as described hereinafter.
This invention further encompasses an improved eucaryotic hos cell for expressing a heterologous protein such as Factor VIII; t-PA; von Willebrand Factor (VWF) ; erythropoietin; lymphokine such as GM-CSF, other CSFs, 11-2, 11-3; etc., or analogs thereof. Factor VIII analogs are described, e.g. i International Applications PCT/US87/01299 and PCT/US87/00033 an in U.S. Serial No. 068,865 (filed July 2, 1987), the contents of which are hereby incorporated by reference. t-PA analogs are described e.g. in U.S. Serial Nos. 861,699; 853,781; 825,104 and 882,051 and in PCT/US87/00257, the contents of which are hereby incorporated by reference. The improved host cell of this invention comprises a host cell transformed or transfected with an anti-sense expression vector of this invention, or the progeny thereof. The improved host cell may be a bacterial, yeast, fungal, plant, insect or mammalian cell or cell line, and is preferably a mammalian cell or cell line.
Established cell lines, including transformed cell lines, are suitable as hosts. Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants (including relatively undifferentiated cells such as hematopoetic stem cells) are also suitable. Candidate cells need not be genotypically deficient in a selection gene so long as the selection gene is dominantly acting.
The host cells preferably will be established mammalian cell lines. For stable integration of vector DNA into chromosomal DNA, and for subsequent amplification of the integrated vector DNA, both by conventional methods, CHO (Chinese Hamster Ovary) cells are presently preferred. Alternatively, vector DNA may include all or part of the bovine papilloma virus genome (Lusky et al., 1984, Cell 2_6:391-401) and be carried in cell lines such as C127 mouse cells as a stable episomal element. Other usable mammalian cell lines include HeLa, COS-1 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HAK hamster cell lines and the like.
The improved host cell, or the progeny thereof, may further be transformed or transfected with one or more expression vectors capable of directing the expression of the desired protein. This may be accomplished directly, i.e., by transforming or transfecting the host cell or its progeny with an expression vector encoding the desired protein, prior or subsequent to transformation or transfection of the host cell with the anti- sense vector of this invention. Alternatively, this may be accomplished "indirectly", i.e., by fusion of cells transformed or transfected with the anti-sense vector or their progeny wi cells transformed or transfected with the vector encoding t desired protein. Suitable vectors for the expression of a lar number of diverse proteins are known in the art and are eith publicly available or may be synthesized by purely convention techniques. Vectors containing DNA encoding the followin proteins, for example, have been deposited with the American Typ Culture Collection (ATCC) of Rockville, MD: Factor VIII (pSP64 VIII, ATCC No. 39812); a Factor VIII analog,"LA", lacking 58 amino acids (pDGR-2, ATCC No. 53100) ;t-PA and analogs thereo (see e.g. International Application WO 87/04722, published 1 August 1987); VWF (pMT2-VWF, ATCC No. 67122); EPO (pRKl-4, ATC No.39940; pdBPVMMTneo 342-12 (BPV-type vector, ATCC No.37224) and GM-CSF (pCSF-1, ATCC No. 39754) .
An improved method is thus provided for producing a heterologou protein, e.g. Factor VIII, etc. The method comprises culturing eucaryotic host cell transformed with a vector capable o directing the expression of the heterologous protein, or th pregeny thereof, the host cell or its progeny being additionall transformed or transfected with (a) an anti-sense GRP78/Bi vector of this invention; (b) a vector, preferably amplified t multi-copy number, containing a DNA sequence substantially th same as the following heterologous DNA sequence, or a portio thereof so long as it is capable of reducing or preventing Bi induction under conditions which otherwise typically induce Bi expression:
(5 ' )
S a I
CGGGGGCCCA ACGTGAGGGG AGGACCTGGA CGGTTACCGG CGGAAACTGG TTTCCAGGTG
Pvu I AGAGGTCACC CGAGGGACAG GCAGCTGCTC AACCAATAGG ACCAGCTCTC AGGGCGGATG
CGCCTCTCAT TGGCGGTCCG CTAAGAATGA CCAGTAGCCA ATGAGTTCGG CTGGGGGGCG
Rsa I
CGTACCAGTG ACGTGAGTTG CGGAGGAGGC CGCTTCGAAT CGGCAGCGGC CAGCGTTGGT
Stu I GGCATGAACC AACCAGCGGC CTCCAACGAG TAGCGAGTTC ACCAATCGGA GGCCTCCACG
Bssh I ACGGGGCTGC GGGGAGGATA TATAAGCCGA GTCGGCGACC GGCGCGCTCG AATAACCCGG
(3») (single, coding strand shown alone for simplicity) or a DNA sequence at least about 70% homologous thereto; or (c) both (a) and (b) .
The DNA insert in the vector in (b) is believed to contain a regulatory element required for induction of transcription of the GRP78 gene, perhaps by binding with an endogenous trans-acting transcriptional regulatory factor which is produced by the host cell in response to BiP-inducing conditions. It is believed that the factor normally binds to an endogenous transcription control element linked to the endogenous BiP gene and thereby causes increased BiP mRNA levels under BiP-inducing conditions. The presence of the vector in (b) , preferably amplified to multi¬ copy number, is believed to compete with the endogenous transcription control sequence for binding to the transcription initiation factor, and thus to block the BiP induction pathway.
This method permits the production at increased levels of heterologous proteins using eucaryotic, preferably mammalian, host cells which contain reduced levels of BiP. By "reduced levels of BiP", as the phrase is used herein, we mean levels of BiP below, preferably at least 20% below, more preferably least 50% below, and even more preferably at least 75% below, t level of BiP in CHO cells under BiP-inducing conditions such glucose deprivation. Factor VIII overexpression, treatment wi tunicamycin or A23187, etc. BiP levels may be convenientl measured by standard procedures such as immunological assa using antibodies directed to BiP or to BiP-heterologous protei complex. Alternatively, BiP levels may be measured indirectly b measuring endogenous levels of RNA encoding BiP using standar procedures such as Northern or Southern blotting.
This method is believed to produce higher recoverable yields o heterologous proteins, which may otherwise be intractably boun within the ER, owing to decreased ER levels of BiP resulting fro decreased levels of translation of the host cell's endogenou BiP-encoding mRNA, in the case of (a) ; decreased levels o induction of the host cell's endogenous BiP gene, in the case o (b) ; and decreased levels of BiP induction and translation, i the case of (c) . Other methods for achieving reduced endogenou BiP levels which will occur to those skilled in this art ar expected to be operative to a greater or lesser extent than th specific methods disclosed herein, and should thus be viewed a equivalent methods.
In the practice of this invention stable transformants prepare for use in the improved method or their progeny are screened fo decreased expression of BiP and/or expression of the heterologou protein by standard immunological or enzymatic assays. Th presence of anti-sense mRNA or mRNA encoding the heterologou protein and/or DNA encoding the heterologous protein or a DN sequence present in the vectors of (a) and/or (b) , above, may be detected by standard procedures such as Northern or Southern blotting respectively. Transient expression of the anti-sense vector and/or the DNA encoding the heterologous protein during the several days after introduction of the respective vector(s) into COS-1 monkey cells is measured without selection by activity or immunological assay of the proteins in the culture medium.
Following expression of the DNA encoding the heterologous protein, the protein so produced may be recovered, purified, and/or characterized, all by known methods.
This invention also encompasses a "sense" GRP78/BiP expression vector which comprises a DNA sequence encoding GRP78/BiP operatively linked to an expression control sequence. Construction of an exemplary GRP78/BiP expression vector is described in detail below, but it should be understood that other BiP expression vectors may be readily prepared by purely conventional techniques using a GRP78/BiP-encoding DNA sequence and readily available or synthesizable components, as is true for other exemplary vectors of this invention described hereinafter.
This invention also encompasses a eucaryotic host cell, as described above, but which is transformed or transfected with a GRP78/BiP expression vector. Such an engineered host cell or its progeny may be further transformed with an expression vector capable of directing the transcription of a heterologous protein, also as described above. The resultant cell or its progeny may then be cultured in an improved method for producing the heterologous protein, wherein improperly glycosylated or folded heterologous protein is not secreted into the culture medium, but is instead retained within the host cell by virtue of association with intracellular BiP.
Detailed Description of the Invention
We have examined the role of BiP/GRP78 in the processing and secretion of a variety of proteins, including human factor VIII (FVIII) and analogs thereof, human tissue plasminogen activator (tPA) and analogs thereof and human von Willebrand Factor (vWF) in eucaryotic host cells such as stable Chinese hamster ova (CHO) cell lines. FVIII is synthesized as a single chai precursor of about 250 kd and subsequently processed to a "hea chain" of about 200 kd and a "light chain" doublet of about 8 kd. FVIII has a plethora of potential N-linked glycosylatio sites. Twenty of the twenty-five sites are located within th middle one-third of the molecule which has been defined as the domain. (Toole et al.. Nature, 1984) Deletion of this domai to produce the "LA" variant of FVIII results in higher levels o FVIII secretion (Toole et al., PNAS, 1986). tPA has a molecula weight of about 68,000 kd and contains four potential N-linke glycosylation sites of which three are typically occupied (Poh et al., Biochem, 1984). vWF is a large glycoprotein synthesize as an approximately 260,000 kd precursor which forms di ers i the endoplasmic reticulum and is subsequently processed in Golg and post-Golgi compartments to approximately 100,000 and 220,00 kd forms (Bonthron et al.. Nature, 1986). These processed form undergo interdimer disulfide bond formation to form hig molecular weight multimers (Wagner & Marder, J. Cell Biol. 1984) .
Our results indicate that the occupancy of N-linked glycosylatio sites on a protein plays a role in the extent of BiP association. Underglycosylation of a protein results in increased Bi association and retention inside the cell. This block t secretion may be dependent on expression level. We believe tha BiP/GRP78 plays a major role in the processing and transport o secreted glycoproteins.
Results
Association of FVIII and Deleted Form LA with BiP
In order to qualitatively assess the role of BiP/GRP78 in the secretory pathway we examined a variety of stable CHO cell lines by pulse and chase experiments. The time course of association of FVIII and BiP was analyzed by comparing the amount of FVIII which was detected by immunoprecipitation with a monoclonal antibody specific for BiP against that precipitated with a monoclonal specific for FVIII. Following a 1 hour pulse with 35S ethionine roughly 85% of wild-type (wt) FVIII was detected in a complex with BiP as indicated by the amount of FVIII seen in the anti-BiP immunoprecipitation compared to that precipitated by the anti-FVIII monoclonal. Only the 250kD single chain form was found to be associated with BiP. No processed 80kD form was precipitated by the anti-Bip monoclonal although it is present in the cells at this time. BiP was observed to migrate slightly faster than the 80kD doublet.
At the 4h chase time point processed heavy chain of 200kD and the 80kD light chain doublet can be detected in the conditioned medium. Immunoprecipation of the conditioned medium detected a slight amount of BiP. However there was no associated FVIII observed. Intracellularly the amount of FVIII associated with BiP had decreased to less than 50% as the molecule transits through the cell. At the 2Oh chase time point the ratio of BiP- associated to unassociated FVIII changed. The single chain FVIII had begun to degrade as indicated by a smearing of the 250kD band as analyzed by gel electrophoresis and roughly all of this FVIII which remained in the cell after a long chase was ound complexed with BiP. The amount of BiP had increased in the conditioned medium over this time course but an association with secreted FVIII can not be detected. It is worth noting that through the 2Oh chase time course the amount of GRP78 inside the cells does not significantly change. It is secreted or released from damaged cells at a low rate and appears to be a stable cellular protein with a half life greater than 2Oh.
We then examined the association of LA with BiP in a similar time course. LA is a deleted form of FVIII which has only 7 potential N-linked sites compared to 25 en wt FVIII. At the lh pulse ti point roughly 60% of single chain LA is associated with Bi Single chain LA appears as a doublet of approximately 150 kd. with wt FVIII no 80kd forms are observed to be complexed wi BiP.
During the 4h chase period the association of LA and Bi significantly decreases compared to the earlier time point Single chain, processed heavy chain which migrates as a smea around 90 kD, and 80kD light chain doublet can be detected in th 4h conditioned medium by immunoprecipitation with anti-FVII monoclonal. Also present in the medium is trace unassociate BiP. At the 2 Oh chase time point a small amount of LA remains i the cell and the proportion of LA associated with BiP is slight These experiments indicated that LA exhibits a transien association with BiP inside the cell and, in contrast to w FVIII, is not retained intracellularly in a complex with BiP This suggested that the complexity of the wt FVIII glycosylatio may influence the degree of BiP association since deletion of th highly glycosylated region in LA produced a protein which wa associated with BiP to a lesser degree than wt FVIII. In thi regard it is noteworthy that GRP78 is induced to high levels i CHO cells placed under conditions which affect N-linke glycosylation such as glucose starvation or tunicamyci treatment .
The Effect of Tunicamycin on the Association of LA and BiP
This observation that a population of wt FVIII molecules remained inside the cell complexed with BiP after long chase while LA displayed a transient association prompted us to test whether disruption of the glycosylation of LA would result in greater association with BiP. To examine this concept, LA producing cells were treated overnight with lOug/ml tunicamycin. This treatment inhibits N-linked glycosylation and has been reported to induce increased levels of GRP78 synthesis (Munro and Pelham, 1986) . Following a lh pulse with 35S methionine the extracts of untreated or treated cells were immunoprecipitated with anti-FVIII monoclonal or anti-Bip monoclonal. In the absence of tunicamycin, only a small amount of single chain LA at 150 kd was associated with BiP. In the presence of tunicamycin the molecular weight of the LA doublet was reduced and roughly all of this unglycosylated LA was now associated with BiP. Thus disruption of the glycosylation of LA under conditions which should induce increased levels of GRP78 results in increased association with BiP compared to normally glycosylated LA. This suggested that improper glycoslylation of FVIII might influence its association with BiP.
Of particular interest is the detection of a protein induced by tunicamycin treatment which comigrates with the protein identified as BiP by immunoprecipitation with the anti-BiP monoclonal. The molecular weight of BiP does not change following tunicamycin treatment indicating it is not normally N- 1inked glycosylated.
Association of vWF with BiP.
It was possible that the CHO cells were deficient in some aspect of the secretory pathway and so could not properly process a complex glycoprotein. To explore this we examined the processing of vWF in a stable CHO line in a pulse and chase experiment. The precursor form of vWF has 17 N-linked glycosylation sites spread along the molecule. At the lh pulse time point the 260Kda VWF precursor protein is observed inside CHO cells. Roughly 10% of this protein is found complexed with BiP. VWF is efficiently and rapidly secreted such that at the 4h chase point approximately 90% of the 260kda precursor is gone from the cell extract and the conditioned medium contains the processed forms of 275 and 220 kD. These processed forms are not observed intracellularly to any' significant degree, consistent with observations that th processing of the 260kda precursor to the 275 and 220 for occurs rapidly late in the pathway of VWF secretion. At bo the 4h chase and 20h chase points most of the VWF has bee secreted from the cells. Some VWF is still associated with Bi at the 4h point but little if any BiP-VWF complex is observed a the 2Oh chase point. Despite the fact that VWF is a comple glycosylated protein its association with BiP is transient an most of the protein is efficiently secreted from CHO cells. Thi is in contrast to the situation with wt FVIII and indicates tha CHO cells are competent to efficiently secrete a comple glyσoprotein.
Association of tPA with BiP
To further analyze the role of glycosylation on protein secretio and Bip association we examined the processing of t-PA i glycosylated and unglycosylated forms in CHO cells. T-PA has potential N-linked glycosylation sites of which 3 are utilized t-PA appears as a doublet or roughly 68 kD due to variability i the utilization of one of the three glycosylation sites. t-PA3 is genetically engineered mutant in which the three normall utilized N-linked glycosylation sites have been abolished by As to Gin codon changes in the canonical recognition site sequences See International Application No. PCT/US87/00257.
Glycosylated unmodified t-PA (i.e. wild type, "t-PAwt") wa efficiently processed and secreted in a high producing CHO cel line, t-PAwt cell line. At the pulse time point t-PAwt exhibite a slight association with BiP. During the lh and 3h chas periods most of the t-PAwt had been secreted into the medium an little if any association with BiP could be detected intracellularly at these times. Thus, at high intracellular concentrations t-PAwt is correctly processed and secreted without extensive detectable association with BiP. We next examined the processing of t-PA3x in a low producing cell line, t-PA3x-4, to determine if the absence of N-linked glycosylation in t-PA3x would prevent its efficient secretion, in analogy to our observations with LA. This unglycosylated form of t-PA displays little association with BiP and is efficiently secreted into the medium. The time course of its transit through the cell is similar to that observed for t-PAwt. The majority of the protein has left the cell by the lh and 3h chase time points indicating that t-PA3x does not experience a block in the secretory pathway. Thus, in the absence of glycosylation t-PA remains in a secretion competent form which displays little association with BiP.
However, examination of a high producing t-PA3x cell line, t- PA3x-13, indicated that the association of t-PA3x with BiP is dependent on the expression level. t-PA3x-13 produces roughly 200-fold higher levels of t-PA3x that t-PA3x-4. At high expression levels t-PA3x displays a significant association with BiP in sharp contrast to that observed for the t-PA3x-4 line. The amount of t-PA3x associated with BiP decreases slightly between the pulse time point and the lh chase point. However, the amount of t-PA3x found in a complex with BiP remains the same between the lh and 3h chase points. Strikingly, the proportion of t-PA3x associated with BiP increased through the time course such that at the 3h chase point most of the t-PA3x which remained in the cell was in a complex with BiP. During the time course of this experiment t-PA3x is secreted from the cell but there exists a population of the molecules which are not competent for efficient secretion and apparently enter a stable complex with BiP. This situation is highly reminiscent of that observed with wt FVIII described above. In the case of t-PA3x the efficient of secretion and the extent of BiP association of the unglycosylated protein was influenced by the expression level. The Effect of Tunicamycin on the Association of t-PA and BiP
Another way to examine unglycosylated forms of t-PA is to inhib N-linked glycosylation by tunicamycin treatment. I mun fluorescence analysis showed that tunicamycin treatment of PAwt-producing cells results in accumulation of t-PA in t endoplasmic reticulum. When the t-PAwt cell line is treated wi 10 ug/ml tunicamycin for 1 hour the association of th unglycosylated t-PA with BiP is significantly increased compare to t-PAwt. t-PA-BiP complex is detected at the chase time poin and there is some inhibition of secretion. Similar treatment o the t-PA3x-13 cell line did not produce an alteration in th amount of t-PA3x associated with BiP compared to untreated cell and the protein is secreted while a fraction of the intracellula t-PA remains associated with BiP. This pattern of protei processing in tunicamycin treated t-PA3x-13 cells looks simila to the untreated time course. This indicated that the influenc of tunicamycin treatment on t-PAwt secretion was due to th absence of glycosylation on the molecule itself rather than a indirect effect of the tunicamycin.
It is striking that the t-PAwt treated with tunicamycin profil looks very much like that of t-PA3x at high expression levels In both cases a similar proportion of the unglycosylate molecules are apparently not competent for efficient secretio and remain in an intracellular complex with BiP. At lowe expression levels t-PA3x shows no significant association wit BiP. t-PAwt at lower expression levels is affected to a lesse degree by tunicamycin treatment than the high producer cell line. Thus the association of unglycosylated t-PA with BiP i influenced by the intracellular levels of t-PA.
Unglycosylated t-PA appears as doublet in these experiments. t PA is synthesized with a 12-15 amino acid long propeptide at the amino terminus of the protein (Pennica et al. Nature 1983) . Most probably the higher molecular weight band represents the uncleaved pro-t-PA precursor form while the lower band represents the mature form which has been processed to remove the amino terminal propeptide. Since propeptide cleavage occurs in Golgi and post-Golgi compartments and BiP has been localized to the endoplasmic reticulum, only the pro-t-PA precursor form should be present in the same compartment as BiP. Consistent with this interpretations is the observation that only the higher molecular weight species of the doublet is found associated with BiP while only the lower molecular weight species is secreted.
CoexT-ression of GRP78 and FVIII or LA in Cos Cells
A cDNA coding sequence for Chinese hamster GRP78 was placed in the expression vector pMT2 which is a derivative of p91023b and this expression vector (pMTGRP78) was σotransfected into COS cells with wt FVIII (pMT2VIII) or LA (pMT2LA) expression vectors to examine the consequences of overexpression of GRP78 on FVIII secretion. The transient expression of FVIII was monitored by assaying the conditioned medium for FVIII activity. Expression of GRP78 was detected by immunoprecipitation with the anti-BiP monoclonal. pMT2 may be obtained from pMT2-vWF (ATCC No. 67122) as described in detail below.
Coexpression of GRP78 and FVIII in COS cells consistently resulted in a 6-10 fold reduction in the levels of FVIII activity in the conditioned medium (Table I, below) . The effect of two different replicating vectors in the same cell is a decrease in the expression of both vectors. To compensate for this phenom¬ enon, FVIII or LA vectors were always cotransfected with pCSF-1. pCSF-1 is an expression vector for GM-CSF which carries similar replication and transcription elements as pMT2 (Wong et al Science 1985) .Coexpression of LA and GRP78 in COS cells resulted in a 2-3 fold reduction the levels of LA activity in the medium. The degree of decrease of activity of LA and wt FVIII a consistent with the degree of association of FVIII and LA wi BiP in CHO cells. The heavily glycosylated wt FVIII is mo affected by GRP78 expression than LA in the transient COS syst and also displays a stronger association with BiP in stable C cell lines. This data indicates that high levels of GRP78 c interfere with the secretion of FVIII and is suggestive that B and GRP78 are functionally and structurally similar.
EXAMPLES
A. Preparation of GRP78 cDNA
The particular GRP78 cDNA used is a matter of choice. F example, one may use a Chinese hamster cDNA clone, p3C5, obtain as described (Lee et al JBC 1983), or the Chinese hamster ,cD described below. Alternatively a rat cDNA clone may be obtaine also as described (Munro & Pelham, Cell, 1986) . Sequenc analysis has shown that both of these clones encode the sa protein identified as GRP78. At the amino acid level the rat an hamster proteins are 99.4% homologous. Cloning of a functiona GRP78 cDNA may be effected using one or more oligonucleotide derived from the published sequence of GRP78 and purel conventional techniques as described by Lee et al. or Munro Pelham, supra. Alternatively, a cloned rat cDNA may be obtaine from Dr. Pelham, MRC Laboratory of Molecular Biology, Hills Road Cambridge CB2 2QH, England. Additionally, a DNA sequenc encoding any desired GRP78 may be synthesized, e.g. usin overlapping oligonucleotides which together span the desire sequence.
B. Coexpression of Chinese Hamster GRP78 cDNA in Monkey Kidne COS Cells with F(VIII) or LA.
Chinese hamster GRP78 cDNA was placed into a mammalian expressio vector pMT2. This vector is a derivative of p91023B and may be obtained by EcoRI digestion of pMT2-vWF, which has been deposited with the American Type Culture Collection under ATCC No. 67122. EcoRI digestion excises the cDNA insert present in pMT2-vWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB101 or DH5 to ampicillin resistance. Plasmid pMT2 DNA can then be prepared by conventional methods. The 1962 nucleotide open reading frame encoding hamster GRP78 was excised by Pstl and EcoRV digestion. The vector was prepared by EcoRI digestion, the EcoRI ends were filled in using Klenow fragment and then the vector was digested with Pstl.
The fragment from the hamster clone was ligated into the prepared pMT2 vector, although as indicated previously, other eucaryotic expression vectors may also be used. The resultant plasmid pMTGRP78 contains the adenovirus-VA genes, SV40 replication origin including enhancer, adenovirus major late promoter (MLP) including tripartite leader and 5' donor splice site, 3' splice acceptor site, GRP78 cDNA insert in proper orientation relative to the MLP for expression of GRP78, DHFR cDNA insert, SV40 early polyadenylation site and pBR322 sequences.
pMTGRP78 was used to cotransfect COS-1 cells along with the FVIII expression vectors pMT2VIII or pMT2LA (Toole et al., PNAS, 1986) using the DEAE dextran procedure (Kaufman, PNAS, 1985). Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity as described (Toole et al., Nature, 1984). The results of these experiments are summarized in Table I. Previous work has shown that cotransfection of two different expression vectors reduces the level of expression compared to transfection of a single vector. To compensate for this phenomenon the FVIII expression vectors were cotransfected with pCSF-1, a previously described vector which expresses GM-CSF (Wong et al Science 1985) . pCSF-1 is available from the American Type Culture Collection in E. coli MC1061 as ATCC 39754. The results in Table I show tha coexpression of GRP78 and FVIII resulted in roughly six-ten fol reduction in the level of secreted FVIII activity an coexpression of GRP78 and LA resulted in a roughly two-three fol reduction compared to coexpression of FVIII or LA with GM-CSF Analysis, of extracts of COS cells cotransfected with pMTLA an pMTGRP78 or pMT2LA and pCSF-1 and subjected to a pulse/chase 35 methionine label showed that in cells expressing pMTGRP78 more L remained associated with BiP/GRP78 following the chase than wa observed in the pCSF-1 cotransf cted cells. These result indicated that overexpression of GRP78 prevented the secretion o FVIII by the intracellular association of FVIII and GRP78 and th retention of this complex in the cell. This suggested tha otherwise secretion competent FVIII might be trapped inside cell expressing high levels of GRP78 and thus a decrease in GRP7 levels would facilitate the secretion of FVIII and othe secretory proteins.
C. Coexpression of Chinese hamster GRP78 antisense cDNA wit F(VIII) in Monkey Kidney COS cells.
Chinese hamster GRP78 cDNA was placed into pMT2 in the opposit orientation from that in the above-described expression vector. The 1962 nucleotide open reading frame was excised as follows. The hamster GRP78 clone was digested with EcoRv and a Pstl linke was ligated to the blunt EcoRV end. The DNA was then cut wit Pstl to excise the 1962 bp open reading frame. The vector pMT2 was prepared by digestion with Pstl. The fragment from th hamster was ligated into the Pstl site of pMT2. The resultant plasmid pMT B2 was analyzed by extensive restriction digest mapping, and it was determined that the vector carries the GRP78 cDNA sequences such that the 3' end of the GRP78 cDNA was closest to the adenovirus major late promoter.
In this orientation transcripts expressed from the adenovirus major late promoter contain sequence which is the complement of the GRP78 coding sequence. Such a RNA is commonly referred to as an antisense RNA. It has been reported that antisense RNA can interact intracellularly with its complementary sense mRNA and block the synthesis of the encoded protein (Kim and Wold, Cell, 1985) .
pMT2αB2 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md 20852 (USA) under accession number ATCC 40387. It should be noted that the cDNA insert may be excised with Pstl digestion and the excised cDNA re-inserted in either orientation into an alternative expression vector, using synthetic linkers, if necessary. The excised cDNA may also be used as a hybridization probe to identify and clone other DNA molecules encoding BiP proteins or (by probing a genomic library) containing transcriptional regulatory nucleotide sequences for BiP proteins, by conventional methods.
pMTαB2 was used to cotransfect COS-1 cells along with the FVIII expression vector pMT2VIII using the DEAE dextran procedure. Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity. The results of such an experiment are summarized in Table II. In this experiment coexpression of FVIII and antisense GRP78 sequences resulted in a 50% increase in FVIII activity in the conditioned medium compared to coexpression of FVIII and GM- CSF. This data indicates that the introduction of an antisense vector to decrease the intracellular level of GRP78 can result in increased levels of FVIII secretion.
SUBSTITUTE SHEET TABLE I
Cotransfection of FVIII and GRP78 Expression Vectors in
COS-1 Cells
Chromocrenic Activity (milliunits/ml )
No DNA 0 0 0 0 pMT2VIII/pCSF-l 67 93 30 30 pMT2VIII/pMTGRP78 10 19 0 5 pMT2LA/pCSF-l 290 — 536 436
PMT2LA/PMTGRP78 90 -_-; 2_40 2_17
*Shown are the results of four separate experiments. T plasmids indicated were cotransfected into COS-1 cells and the conditioned medium removed for assay by the Kabi Coatest F(VIII) : C method.
TABLE II
Cotransfection of F(VIII) and Antisense GRP78 Expression Vectors in COS-1 Cells
Chromoqenic Activity (milliunits/ml ) pMTVIII/pCSF-1 90 pMTVIII/pMTαB2 135
No DNA 0
The plasmids indicated were cotransfected into COS-1 cells an conditioned medium removed for an assay by the Kabi Coates F (VIII) : C method.
D. Development of CHO cell lines with reduced BJP/GRP78 levels and fusion with FVIII producing cell lines
1) Development of CHO cells with reduced BiP/GRP78 levels
Chinese hamster ovary (CHO) cell lines which are DHFR deficient, CHO" (DUKX-Bll) , were grown in an alpha medium supplemented with lOug/ml each of thymidine, deoxyadenosine and adenosine. Cells were cotransfected with pMTαB2 (20μg) and pSV2Neo (2 g) (ATCC No. 37149) by the calcium phosphate coprecipitation procedure (Kaufman et al JMB 1982) . pSV2Neo codes for resistance to the antibiotic G418 (P. Southern & Berg P. 1982 J. Mol. Appl. Genet. 1 327-341). Forty-eight hours post-transfection the cells were plated in alpha medium supplemented with nuσleosides as above and including Img/ml of G418 in order to select for SV2Neo expression. pMTαB2 contains an intact DHFR coding region in the 3' region of the antisense GRP78 transcript. Thus G418 resistant transformants can be subsequently selected for DHFR expression from this mRNA. Growth in alpha media lacking nucleosides with 10% dialyzed fetal calf serum resulted in DHFR+ colonies. Five colonies were pooled to produce the A6B line. This line was then amplified by selection for growth in the presence of the folic acid analogue methotrexate at a concentration of .02uM.
Following approximately 8 passages in .02uM methetrexate the BiP/GRP78 level in A6B was compared to CHO DUKX by immunoprecipitation of radiolabeled cell extracts with anti-BiP monoclonal and analysis by SDS PAGE. Additionally, the level of BiP/GRP78 was measured by Western analysis using anti-BiP monoclonal antibody. A6B showed reduced levels of BiP/GRP78 compared to the original CHO line. In addition the level of antisense GRP78 RNA derived from pMT B2 in these cells was determined by Northern analysis. 2) Fusion of H9 with BiP/GRP78 reduced cell line
The A6B cell line was fused with a FVIII producing cell l ine , H9 , by standard polyethylene glycol procedure following treatment of the A6B cells with DEPC to render them nonviable (WE Wright , Chap 5 , The S election of Heterokaryons and Cell Hybrids Using the Biochemical Inhibitors Iodoaceta ide and Diethylpyrocarbonate in Techniques in Somatic Cell Genetics, Ed. JW Shay, Plenum Press) . Two days following cell fusion the cells were plated in luM methetrexate and lmg/ml G418. H9 grows in luM methetrexate and G4 Ϊ8 selects for the chromosome containing the antisense GRP78 sequences derived from A6B cells . After eleven days of growth twenty-two colonies were pooled to produce the cell line designated H9XA6B-9. Determination to the level of FVIII procoagulant activity secreted into the conditioned medium by H9xA6B-9 showed that this cell line yielded two-fold greater activity than the original H9 line.
3 ) Fusion of tPA-3x cell line with cell line having reduced level of BiP/GRP78
Another cell line was developed as follows . CHO DUKX cells as above were cotransfected with pMT B2 (20 ug) and pSV2AdA (2 ug) by the calcium phosphate coprecipitation procedure. pSV2AdA codes for adenosine deaminase and allows for cell growth in the presence of cytotoxic concentrations of adenosine and the drug deoxycoformycin(dCF) . Forty-eight hours post-transf ection the cells were plated in alpha medium supplemented with deoxyadenos ine , thymidine , uridine (U) , alanosine (A) , adenosine (A) , and . 03 uM dCF. Growth in AAU and dCF selects for ADA expression. Colonies were pooled to produce the C6B line. This line was subsequently amplified by selection for growth in 0.1 uM and luM dCF. The BiP/GRP78 protein levels were measured by immunoprecipitation of radiolabeled cell extracts and by Western analysis using anti-BiP monoclonal. The level of GRP78/BiP RNA was also determined by Northern analysis. C6B showed reduced levels of BiP/GRP78 protein and RNA compared to CHO DUKX.
The C6B line growing in 1 uM dCF was fused with a tPA3x producing cell line tPA3x-9. Two days following cell fusion, cells were plated into alpha medium containing AAU, 1 uM dCF and 0.02 uM methotrexate. tPA3x-9 grows in 0.02 methotrexate and dCF selects for the chromosome containing antisense GRP78 sequences. After 11 days of growth 9 colonies were pooled to produce the laE line. Determination of the level of tPA activity secreted into the conditioned medium showed that this line yielded 2-5 fold greater activity than the original tPA3x-9 line.
E. Preparation and use of vectors containing regulatory sequences for BiP/GRP78 transcription
A DNA sequence containing the BiP/GRP78 regulatory element was removed from pUC291R (Lin et al., Mol. Cell Biol., 1986) by digestion of the plasmid with Sma I and Hindi. The DNA fragment so obtained contains the 291 (Smal/Stul) nucleotide sequence bearing the regulatory element required for induction of the rat GRP78 gene. Alternatively, the 360 nucleotide sequence shown above on page 7, or a portion thereof, may be synthesized by purely conventional methods, e.g. through the synthesis of overlapping oligonucleotides which together span the desired sequence. It should be understood that the corresponding GRP78 regulatory sequence derived from other species should also be usable in this invention, whether isolated from a genomic DNA library or chemically synthesized. It is believed that a trans-acting factor or factors may bind to regulatory sequence(s) within the DNA fragment so obtained and thus mediate induction of GRP78 transcription. It has been reported that such DNA fragments can compete for the hypothesized trans-acting factor(s) n vivo (Lin et al., Mol. Cell Biol., 1986).
Operability of the regulatory fragment to be used may be conveniently assayed by methods such as described by Lin et al., Mol. Cell Biol., 1986.
The regulatory DNA sequence to be used is then inserted into a conventional expression vector for use in eucaryotic cells, preferably mammalian cells, either directly or with synthetic linkers if desired. By way of example, the regulatory sequence may be inserted with synthetic EcoRI linkers into the EcoRI site in expression vector, pMT2. pMT2 may be obtained by EcoRI digestion of pMT2-VWF, which has been deposited (29 May 1986) with the American Type
Culture Collection of Rockville, Maryland (USA) under accession number ATCC 67122. EcoRI digestion excises the cDNA insert present in pMT2-VWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli
HB101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods. Of course, other expression vectors known in the art may be used in place of pMT2, using appropriate linkers as desired or necessary.
The expression vector containing the regulatory sequence is then cotransfected or cotransformed into the desired host cell with one or more selectable, amplifiable markers, as is known in the art, and gene copy number of the heterologous DNA may be amplified as desired using conventional methods. The presence of multiple copies of the regulatory sequence in the cellular genome should compete with the endogenous GRP78 expression control sequences for binding wit the trans-acting factor(s) following induction by conditions such as blockage of N- linked glycosylation, over-expression of FVIII : c or analogs thereof , etc. Such competition for trans-acting factors has been reported for a metalothionein I gene (Seguin et al . , Nature, 1984) and suggested for heat shock proteins (McGarvy and Lindquist , Proc . Natl . Acad. Sci . , 1986) . Induction of transcription of the endogenous BiP gene, and thus the induced levels of BiP protein in the resulting cells and their progeny would thus be significantly reduced. Preferably the ratio of induced BiP transcription levels to normal BiP transcription levels is less than about 20 , more preferably less than about 10 , even more preferably less than about 5 , and especially preferably less than about 1.
Transformants or transf ectants , or the progeny thereof, which contain the vector-borne regulatory sequence may additionally be transformed or trans fected with an expression vector capable of directing the synthesis of a desired heterologous protein. Alternatively, they may be fus ed with other c el ls which had been previously transformed or transfected with an expression vector capable of directing the synthesis of the des ired heterologous protein . Suitable vectors capable of directing the synthesis of heterologous proteins are known in the art and discussed previously.
F. Conclusions of BJP/GRP78 Association study
From experiments including those described above, we draw the following conclusions:
1. wt FVIII is associated with BiP and most of the FVIII which is never secreted remains associated with BiP. 20 out of 25 N-linked glycosylation sites are clustered in middle third of the FVIII protein.
2. LA, a deleted form of FVIII which has 18 of 20 clustered glycosylation sites removed, is more efficiently secreted than wt FVIII exhibits a transient association with BiP.
3. The association of LA with BiP can be significantly increased by treatment of cells with the N-linked glycosylation inhibitor tunicamycin.
4. VWF, a complex glyσoprotein which is efficiently secreted by CHO cells, exhibits only a transient association with BiP. The 17 glycosylation sites on VWF are spaced along the molecule rather than clustered as on wt FVIII.
5. tPA exhibits only a slight transient association with BiP. However inhibition of N-linked glycosylation by tunicamycin results in the intracellular retention of some of the unglycosylated molecules in a complex with BiP.
6. tPA3x, an engineered mutant of t-PA which has had three potential N-linked glycosylation sites abolished by replacement of Asn with Gin exhibits only a slight association with BiP at low expression levels. However, at high expression levels a fraction of the unprocessed protein displays a stable association with BiP and is apparently not secreted effeciently. This behavior is similar th that observed for wt t-PA when glycosylation is inhibited.
7 . Intracellular retention of unglycosylated tPA in a complex with BiP is dependent on expression level. tPA3x at low expression levels is not associated with BiP and is effeciently secreted. At 200-fold higher expression levels a significant proportion of tPA3x is associated with BiP. This intracellular retention is similar to that observed for the high producer wt tPA cell line when N-linked glycosylation is inhibited. In a low producing wt tPA cell l ine , H12 B , the eff ect of inhibition of N-linked glycosylation is less pronounced than in higher-producing cells . This suggests that unglycosylated tPA may aggregate when present at high concentrations in the ER leading to its association with BiP.
8. BiP may associate with improperly glycosylated or folded proteins in the endoplasmic reticulum and prevent the ir secretion. BiP probably functions to clear aggregated proteins from the endoplasmic reticulum in an analogous function to hsp70 in heat shocked nucleoli. The problem of protein aggregation or insolubility in the ER may be exacerbated by the high expression levels now attainable by reσombinant DNA expressioin techniques and for some glycσproteins such as FVIII aggregation and consequent association with BiP may prove a barrier to high level secretion.
9. The 20 clustered glycosylation sites in the middle of wt FVIII may be inefficiently glycosylated resulting in aggregation of improperly folded molecules and stable association with BiP . It is also possible that this heavily glycosylated domain assumes a conformation which BiP recognizes as aberrant even if N-linked glycosylation is appropriate. In this situation secretion competent molecules may be trapped in a complex with BiP and reduced levels of BiP may result in higher levels of secretion.
10. Reduction of BiP levels in FVIII producing cell lines results in increased secretion of FVIII acitvity into the conditioned medium. Thsu CHO cell lines with reduced levels of BiP may be of utility in the expression of certain complex glycoproteins.
31A
1. Bole , D . G. , Hendershot, L. . , and Kearney J.F. (19S6) Postranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secrating hybridomas. J.Cell Biol.102 : 1558-1566.
2. Lewis ,M. J. and Pelham H.R.B. (1985) Involvement of ATP in the nuclear and nucleolar functions of the 70Kd heat shock protein. EMBO J.4:3137-3143.
3. unro, S. and Pelham H.R.B. (1986) An hsp70-like protein in the ER: identity with the 78Kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46:291-300.
4. Shiu , R. P . , Pouyssegur , . , and Pasten I. (1977) Glucose deprivation accounts for the induction of two transf omat ion- sensitive membrane proteins in Rous sarcoma virus -trans formed chick embryo fibfoblasts. Proc. atl. Acad. Sci. USA 74:3840-3844.
5. Chappell ,T.G. , Welch, W.J., Schlossman, D.M. , Palter, K.B., Schlesinger,M. J. , and Rothman, J.Ξ. (1986) Uncoating ATPase is a member of the 70- kD family of stress proteins. Cell 45:3-13.
6. Ungewickell , E . (1985) The 70Kd mammalian heat shock proteins are structurally and functionally realated to the uncoating protein that releases clathrin triskelia from coated vesicles .EMBO J.4:3385-3391.
7. Pelham, H.R.B. (1986) Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 46:959-961.
8. Schlesinger,M. J. (1986) Heat shock proteins: the search for functions . J . Cell Biol.103 :321-325.
9. Williams D.B. , Swiedler,S.J. ,and Hart, G.W. (1985) Intracellular transport of membrane glcoproteins : two closely related histoco patibility antigens differ in their rates of transit to the cell surface. .Cell Biol.101: 725-734.
10.Lodish,H.F. ,Hong,N. , Snider ,M. , Strous,G. J. (1983 ) Hepatoma secretory proteins migrate from rough endoplasmic reticulum to golgi at characteristic rates. ature 304:80-83.
11. itting ,T. and Kabat,D. (1982) Evidence for a glycoprotein signal involved in transport between subcellular organelles. J.Biol.Chem. 257:14011-14017.
12. Blobel,G.and Dobberstein,B. (1975) Transfer of proteins across membranes. II Reconstitution of functional rough microsomes from heterologous components . J . Cell Biol.67:852-862. 13. Farquhar,M.G. (1986) Progress in unraveling pathways of golg traffic". Ann. Rev. Cell Biol.1: 447-438.
14. Kornfeld, R. and Kornfeld, s. (1985) Assembly of asparigine linked oligosaccharides. Ann. Rev. Biochem. 54:631-664
15. Walter, P. , Gilmore, R. amd Blobel,G. (1984) Protei translocatiσn across the endoplasmic reticulum. Cell 38:5-8.
16.Gething,M. J. , McCammon,K., and Sambrook J. (1986) Expressio of wild-type and mutant forms of influenza hemagglutinin: th role of folding in intracellular transport. Cell 46:939-950.
17.Ξharma, S. , Rogers, L. , Brandsma,J. , Gething, M.J., an Sambrook, J. (1985) SV40 T antigen and the exocytic pathway. EMB J. 4:1479-1489.
18. Shiu,R. P. C. , Pouyssegur,R. , and Pasten,I. (1977) Glucos depletion accounts for the induction of two tranf omation sensitive membrane proteins in Rous sarcoma virus -trans forme chick embryo fibroblasts. Proc. Nat. Acad. Sci. USA 74, 3840-3844.
19. Haas, I. G. and Wable,m. (1983 ) Immunoglobulin heavy chai binding protein. Nature 306,387-389.
20. Olden, K. , Pratt, R.M., Jawosski,C, and Yamamda, K.M. (1979) Evidence for role of glycoprotein carbohydrates in membrane transport: specific inhibition by tunicamycin. Proc. atl. cad. Sci. USA 76,791-795.
21. Pouyssegur, J. , Shiu,R. P.C. , and Pasten,I. (1977) Induction of two transformation-sensitive membrane polypeptides in normal fibriblasts by a block in glycoprotein synthesis or glucose deprivation. Cell 11, 941-947.
22. Wagner , D. D. and Marder , V. J . ( 1984 ) Biosynthesis of von Willebrand Protein by human endothelial cells: processing steps and their intracellular localization. J.Cell Biol. 99,2123-2130.
23.0rci, L. , Ravazzola, M. , Amherdt, M. , Madsen, 0., Vassalli, J. , and Perrelet,A. (1985) Direct identification of prohormone Conversion site in insulin-secreting cells. Cell 42,671-681.
24. Pennica, D. , Holmes, W. , Kohr,W., Harkins ,R.N . , Vehar,G.A., Ward,C.A., Bennett, W.F. , Yelverton,E. , Seeburg,P.H. , Heyneker,H., Goeddel,D.V. , and Collen, D. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301,214-221.
25. Kaufman, .J. , Wasley,L.C, Spiliotes , A. J. , Gossels, S . D. , Latt,S.,A., Larsen,G.R., and Kay,R.M. (1985) Coa plification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary 31C
cells. Mol. Cell Biol. 5,1750-1759.
26.Toole,J.J. , Pittman,D.D. , Orr,E.C, Murtha,P., Wasley,L.C, and Kaufman,R.J. (1986) A large region (95 kDa) of human factor VIII is dispensible for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U.S.A. 83,5939-5942.
27.Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227,680-685.
28. oole, J. J. , Knopf,J.L., Wozney,J.M., Sultzman,L.A. , Buecker,J.L. , Pittman,.D.D. , Kaufman,R.J. , Brown,E., Shoemaker,C. , Orr,Ξ.C, Amphlett,G.W. , Foster,W.B., Coe,M.L. , Knutson,G.J. , Fass,D.N., and Hewick,R.M. (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312,342-347.
29. Gibson,R. , Schlesinger, S., and Kornfeld,S. (1979) The nonglycosylated glycoprotein of vesicular sto atitus virus is temperature-sensitive and undergoes intracellular aggregation at elevated temperatures. J. Biol. Chem. 254,3600-3607.
30.Gibson,R. , Kornfeld,S., and Schlesinger,S. (1981) The effect of oligosaccharide chains of different sizes on the maturation and physical properties of the G protein of vesicular stomatitus virus, r.Biol. Chem. 256,456-462.
31.Takasuki,A. , Kohno,K., amd Tamura,G. (1975) Inhibition of biosynthesis of polyisoprenol sugars in chick embryo microsomes by tunicamycin. Agric. Biol. Chem. 39,2089-2091.
32. Bonthron, D.T. , Handin,R.I., Kaufman,R.J. , Wasley,L.C, Orr,E.C, Mitsock,L.M. , Ewenstein,B. , Loscalzo,J., Ginsburg,D. , Orkin,S.H. (1986) Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 324,270-273.
33. Pohl,G., Kallstrom,M. , Bergsdorf, . , Wallen,P., and Jornvall,H. (1984) Tissue plasminogen activator: peptide analysis confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 23,3701-3707.
3 ID
34 . Dunphy & Rothman, 1985 , "Compartmental Organization of the Golgi Stack, " Cell , 42 : 13-21.
35. Fitting & Kabat, 1982 , "Evidence for a glycoprotein signal involved in transport between subσellular organelles : 2 membrane glycoproteins encoded by murine leukemia virus reach the cell surgace at different rates , " J . Biol . Chem.
..257.(23 ) : 1401-1417.
36. Lin et al., 1986, "A Calcuim Ionophore-Inducible Cellular Promoter Is Highly Active and Has Enhancerlike Properties," Mol. Cell. Biol. 1(4) :1235-1243.
37. Resendez et al. , 1985, "Calcium Ionophore A23187 Induces Expression of Glucose-Regulated Genes and Their Heterologous Fusion Genes," Mol. Cell. Biol. 5.(6) :1212-1219.
38. Chang et al., 1987, "Rat gene encoding the 78-kDa glucose- regulated protein GRP78: Its regulatory seqiences and the effect of protein glycosylation on its expression," Proc. Natl. Acad. Sci., USA 84:680-684.
39. Wong et al., 1985, "Human Recombinant Granulocyte-Macrophage Colony-Stimulating Factor: A Multilineage Hematopoieti, " Science, 230(4730) :1171-73.
40. Lee et al., 1983, "Transcriptional regulation of two genes specifically induced by glucose starvation in a hamster mutant fibroblast cell line," J. Biol. Chem. 258:597-603.
41. Kim & Wold, 1985, "Stable Reduction of Thymidine Kinase Activity in Cells Expressing High Levels of Anti-Sense RNA", Cell, 42:129-138.
42. Seguin et al., 1984, "Competition for Cellular Factors that Activate Metallothionein Gene Transcription," Nature, 312:781-785.
43. McGarry & Lindquist, 1986, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci., USA 83:399-403.

Claims

32 What is claimed is:
1. An anti-sense expression vector comprising a DNA sequence encoding a GRP78 protein or a portion thereof operatively linked in reverse orientation to an expression control sequence such that transcription of the DNA sequence produces an anti-sense mRNA capable of hybridizing to a GRP78-encoding mRNA.
2. An improved eucaryotic host cell for expressing a heterologous protein which comprises a eucaryotic host cell transformed with a vector of claim 1, or progeny thereof.
3. A yeast, fungal insect, plant or mammalian host cell of claim 2.
4. An improved host cell of claim 2 which is further transformed with a vector capable of directing the expression of a heterologous protein, or progeny thereof.
5. An improved host cell of claim 4, wherein the heterologous protein is Factor VIII or an analog thereof.
6. An improved method for producing a heterologous protein which comprises culturing a host cell or progeny thereof wherein the host cell is transformed with a vector capable of directing the expression of the heterologous protein, the transformed host cell being additionally transformed with a vector selected from the group consisting of:
a. a vector of claim 1;
b. a vector containing the DNA sequence: 33 (claim 6 , continued)
(5 ' )
CGGGGGCCCA ACGTGAGGGG AGGACCTGGA CGGTTACCGG CGGAAACTGG TTTCCAGGTG AGAGGTCACC CGAGGGACAG GCAGCTGCTC AACCAATAGG ACCAGCTCTC AGGGCGGATG CGCCTCTCAT TGGCGGTCCG CTAAGAATGA CCAGTAGCCA ATGAGTTCGG CTGGGGGGCG CGTACCAGTG ACGTGAGTTG CGGAGGAGGC CGCTTCGAAT CGGCAGCGGC CAGCGTTGGT GGCATGAACC AACCAGCGGC CTCCAACGAG TAGCGAGTTC ACCAATCGGA GGCCTCCACG ACGGGGCTGC GGGGAGGATA TATAAGCCGA GTCGGCGACC GGCGCGCTCG AATAACCCGG (3')
or a portion thereof;
c. a vector containing a DNA sequence at least 70% homologous to the DNA sequence of (b) ; and,
d. combinations of vectors (a) , (b) , and/or (c) .
7. An improved method of claim 6, wherein the heterologous protein is Factor VIII:c or an analog thereof.
PCT/US1987/002971 1986-11-14 1987-11-13 Eucaryotic expression system WO1988003558A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE88900621T DE3789017D1 (en) 1986-11-14 1987-11-13 Eucaryotisches expressionssystem.
AT88900621T ATE101195T1 (en) 1986-11-14 1988-05-26 EUCARYOTIC EXPRESSION SYSTEM.
KR1019880700824A KR890700164A (en) 1986-11-14 1988-07-14 Eukaryotic cell expression system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93138186A 1986-11-14 1986-11-14
US931,381 1986-11-14
US010,351 1987-02-03
US07/010,351 US4912040A (en) 1986-11-14 1987-02-03 Eucaryotic expression system

Publications (1)

Publication Number Publication Date
WO1988003558A1 true WO1988003558A1 (en) 1988-05-19

Family

ID=26681064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/002971 WO1988003558A1 (en) 1986-11-14 1987-11-13 Eucaryotic expression system

Country Status (9)

Country Link
US (1) US4912040A (en)
EP (1) EP0289597B1 (en)
JP (1) JPH01501363A (en)
KR (1) KR890700164A (en)
AU (1) AU1100288A (en)
CA (1) CA1297436C (en)
DE (1) DE3789017D1 (en)
ES (1) ES2013324A6 (en)
WO (1) WO1988003558A1 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007071A1 (en) * 1990-10-19 1992-04-30 The Board Of Trustees Of The University Of Illinois Methods and applications for efficient genetic suppressor elements
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
WO1994011503A2 (en) 1992-11-13 1994-05-26 Genetics Institute, Inc. Chimeric factor viii
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
WO1997020055A1 (en) * 1995-11-07 1997-06-05 Interpharm Laboratories Ltd. Use of anti-sense sequences to increase responsiveness to gene amplification
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
US5866327A (en) * 1990-10-19 1999-02-02 Board Of Trustees Of The University Of Illinois Association of kinensin with sensitivity to chemotherapeutic drugs
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6268134B1 (en) 1993-09-07 2001-07-31 Board Of Trustees Of University Of Il Method and applications for efficient genetic suppressor elements
US6399377B1 (en) 1995-11-27 2002-06-04 Yves Mory Use of anti-sense sequences to increase responsiveness to gene amplification
US6683159B2 (en) 1998-03-12 2004-01-27 Genetics Institute, Llc Methods for producing factor VIII proteins
US6838437B2 (en) 1996-04-24 2005-01-04 University Of Michigan Inactivation resistant factor VIII
JP2007509616A (en) * 2003-10-27 2007-04-19 ユニバーシティ オブ サウザーン カリフォルニア Methods and compositions for modulating apoptosis
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
EP2520586A1 (en) 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US9050318B2 (en) 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015106052A1 (en) 2014-01-10 2015-07-16 Biogen Ma Inc. Factor viii chimeric proteins and uses thereof
US9376672B2 (en) 2009-08-24 2016-06-28 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10010622B2 (en) 2011-07-08 2018-07-03 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
US10221455B2 (en) 2012-01-12 2019-03-05 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
EP3505179A1 (en) 2012-01-12 2019-07-03 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
US10421798B2 (en) 2012-02-15 2019-09-24 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
DK0574402T3 (en) 1990-11-26 1998-05-18 Chiron Corp Expression of PACE in Host Cells and Methods for Using Them
US6562588B2 (en) * 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
ES2128562T3 (en) * 1993-05-17 1999-05-16 Genentech Inc DEFICIENT CELLS IN SIALIDASA.
AU1960495A (en) * 1995-03-17 1996-10-08 Chihiro Koike Transformant of nonprimatial mammal having serotype of advanced primate expressed by foreign gene transduction and process for producing the same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
SI1141028T1 (en) 1998-12-23 2010-05-31 Pfizer Human monoclonal antibodies to ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
AU2002231368C1 (en) * 2001-01-05 2018-08-16 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
JP2005519580A (en) * 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Human anti-pneumococcal antibody derived from non-human animals
DE60235989D1 (en) 2001-06-26 2010-05-27 Amgen Fremont Inc ANTIBODIES AGAINST OPGL
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc Multiple wavelength illuminator
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP4563171B2 (en) 2002-05-24 2010-10-13 シェーリング コーポレイション Neutralizing human anti-IGFR antibody
EP1572946B1 (en) 2002-09-06 2012-03-14 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
MXPA05005921A (en) 2002-12-02 2005-10-19 Abgenix Inc Antibodies directed to tumor necrosis factor and uses thereof.
AU2004224390A1 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
KR101531400B1 (en) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
TW201319088A (en) 2003-07-18 2013-05-16 Amgen Inc Specific binding agents to hepatocyte growth factor
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
ES2321088T3 (en) 2003-08-08 2009-06-02 Amgen Fremont Inc. ANTIBODIES DIRECTED AGAINST THE PARTIROID HORMONE (PTH) AND USES OF THE SAME.
AR045563A1 (en) * 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
EP1670507A4 (en) * 2003-09-12 2007-10-17 Antigenics Inc Vaccine for treatment and prevention of herpes simplex virus infection
MX350383B (en) * 2004-01-09 2017-09-04 Pfizer ANTIBODIES TO MAdCAM.
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
ME00226B (en) 2004-07-15 2011-02-10 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CA2573821A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AU2005269265B2 (en) 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
EP1817590A2 (en) 2004-11-08 2007-08-15 Schering Corporation Tumor association of mdl-1 and methods
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
ATE504602T1 (en) 2004-12-20 2011-04-15 Amgen Fremont Inc BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
US9487581B2 (en) 2005-03-08 2016-11-08 Pfizer Inc. Anti-CTLA-4 antibody compositions
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
CA2604357C (en) 2005-04-26 2012-01-17 Pfizer Inc. P-cadherin antibodies
WO2007011941A2 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-b7rp1 neutralizing antibodies
WO2007019541A2 (en) * 2005-08-08 2007-02-15 Onconon, Llc. Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AU2006297571B2 (en) 2005-09-07 2012-03-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
CA2633956C (en) 2005-12-13 2016-12-06 Olivia Raeber Binding proteins specific for insulin-like growth factors and uses thereof
EP3168234A1 (en) 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
MX2008012754A (en) * 2006-04-07 2009-04-27 Us Gov Health & Human Serv Antibody compositions and methods for treatment of neoplastic disease.
SMP200800060B (en) 2006-04-07 2009-07-14 Procter & Gamble Antibodies that bind the human protein tyrosine phosphatase beta (hptbeta) and their uses
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
US7745584B2 (en) * 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
ES2613957T3 (en) 2006-08-04 2017-05-29 Medimmune Limited Antibodies against ERBB2
CA2661446C (en) 2006-08-11 2017-11-21 Csl Limited Treatment of pulmonary disease conditions
PT2121751T (en) 2006-12-08 2017-04-18 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angptl3
CL2008002444A1 (en) 2007-08-21 2009-09-04 Amgen Inc Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
NZ584726A (en) * 2007-09-26 2012-09-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
ES2536877T3 (en) 2007-10-26 2015-05-29 Csl Limited Cytokine muteins
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
PE20091269A1 (en) 2007-12-14 2009-09-09 Medarex Inc BINDING MOLECULES TO THE HUMAN OX40 RECEIVER
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
SG177689A1 (en) 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
DK2477656T3 (en) 2009-09-15 2017-06-26 Csl Ltd TREATMENT OF NEUROLOGICAL CONDITIONS
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
EP3351558B1 (en) 2009-11-13 2020-03-11 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
JP6022444B2 (en) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション Heterodimeric protein and method for producing and purifying it
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
KR102001686B1 (en) 2011-04-07 2019-07-18 암젠 인크 Novel egfr binding proteins
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2766044B1 (en) 2011-10-13 2019-12-11 Aerpio Therapeutics, Inc. Treatment of ocular disease
MX363351B (en) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer.
CN104271599A (en) 2011-11-08 2015-01-07 辉瑞公司 Methods of treating inflammatory disorders using anti-M-CSF antibodies
US20140314667A1 (en) 2011-11-16 2014-10-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
MX363819B (en) 2012-02-08 2019-04-03 Igm Biosciences Inc Cdim binding proteins and uses thereof.
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
PL3431492T3 (en) 2012-04-27 2021-07-05 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
NZ703724A (en) 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6433889B2 (en) 2012-06-15 2018-12-05 ファイザー・インク Improved antagonistic antibodies against GDF-8 and uses thereof
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
EP2928917B1 (en) 2012-12-07 2018-02-28 Pfizer Inc Engineered monomeric antibody fragments
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
PL2958944T3 (en) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Antidll3-antibody-pbd conjugates and uses thereof
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
PE20160674A1 (en) 2013-08-28 2016-07-21 Stemcentrx Inc METHODS OF CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
TWI790593B (en) 2014-08-19 2023-01-21 美商默沙東有限責任公司 Anti-tigit antibodies
AR101942A1 (en) 2014-08-27 2017-01-25 Amgen Inc THREE-TYPE METALOPROTEINASE FABRIC INHIBITOR VARIATIONS (TIMP-3), COMPOSITIONS AND METHODS
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
JOP20200116A1 (en) 2015-04-24 2017-06-16 Amgen Inc Methods for treating or preventing migraine headache
ES2924402T3 (en) 2015-10-02 2022-10-06 Symphogen As Anti-PD-1 Antibodies and Compositions
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
EP3370724A2 (en) 2015-11-03 2018-09-12 GlycoMimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
JP2019503985A (en) 2015-11-03 2019-02-14 グリコミメティクス, インコーポレイテッド Monoclonal antibodies, methods and compositions for the production of hematopoietic stem cells, and methods of using them
BR112018012352A2 (en) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anti-lag3 antibodies and antigen binding fragments
MX2018007859A (en) 2015-12-23 2018-11-09 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists.
DK3443009T3 (en) 2016-04-12 2021-12-13 Symphogen As ANTI-HOUR-3 ANTIBODIES AND COMPOSITIONS
RU2680011C2 (en) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Trispecific il-17a, il-17f and other proinflammatory molecules antibodies
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
CN117567621A (en) 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 anti-LAG-3 antibodies and compositions
CA3041717A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
MA49042A (en) 2017-04-05 2020-02-12 Symphogen As TARGETING POLYTHERAPIES PD-1, TIM-3 AND LAG-3
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
RU2665790C1 (en) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Monoclonal pd-l1 antibody
JOP20190259A1 (en) 2017-05-31 2019-10-31 Amgen Inc Anti-jagged1 antigen binding proteins
KR20200019122A (en) 2017-06-20 2020-02-21 암젠 인크 Methods of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptors (GIPR) in combination with GLP-1 agonists
PE20200616A1 (en) 2017-07-14 2020-03-11 Pfizer ANTIBODIES AGAINST MADCAM
US20210346513A1 (en) 2017-08-04 2021-11-11 Amgen Inc. Method of conjugation of cys-mabs
EA039662B1 (en) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1
RU2698048C2 (en) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to il-5rα
CA3083969A1 (en) 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
HUE054403T2 (en) 2018-01-26 2021-09-28 Regeneron Pharma Anti-tmprss2 antibodies and antigen-binding fragments
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
MA52175A (en) 2018-03-26 2021-02-17 Regeneron Pharma ANTI-PFRH5 ANTIBODIES AND THEIR ANTIGEN BINDING FRAGMENTS
CA3103531A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
RU2706298C1 (en) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" PaCas9 NUCLEASE
RU2724469C2 (en) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds to cd20
AU2020214812A1 (en) 2019-02-01 2021-09-23 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins
JP2022526764A (en) 2019-03-22 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド EGFRxCD28 multispecific antibody
RU2734432C1 (en) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
CA3143154A1 (en) * 2019-06-10 2020-12-17 CHO Plus Inc. Cell lines for high level production of protein-based pharmaceuticals
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
CN115023439A (en) 2019-09-06 2022-09-06 西福根有限公司 anti-CD 73 antibodies
RU2753282C2 (en) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION
US20220389099A1 (en) 2019-11-04 2022-12-08 Amgen Inc. Methods for treating leukemia
IL293286A (en) 2019-12-06 2022-07-01 Regeneron Pharma Vegf mini-traps and method of use thereof
JP2023513124A (en) 2020-02-10 2023-03-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Anti-TMPRSS2 Antibodies and Antigen-Binding Fragments
PE20221893A1 (en) 2020-04-02 2022-12-13 Regeneron Pharma ANTIBODIES AGAINST SARS-COV-2 SPICLE GLYCOPROTEIN AND ANTIGEN-BINDING FRAGMENTS
EP4143227A2 (en) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies
CN115803009A (en) 2020-05-08 2023-03-14 瑞泽恩制药公司 VEGF traps and microwells and methods for treating ocular diseases and cancer
BR112022024149A2 (en) 2020-05-26 2023-02-07 Regeneron Pharma ANTI-SARS-COV-2 SPIKE ANTI-GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
IT202000015754A1 (en) 2020-06-30 2021-12-30 Fond Toscana Life Sciences ANTIBODIES TO CORONAVIRUS
EP4175982A1 (en) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
EP4185322A2 (en) 2020-07-24 2023-05-31 Amgen Inc. Immunogens derived from sars-cov2 spike protein
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
IT202100003470A1 (en) 2021-02-16 2022-08-16 Fond Toscana Life Sciences VACCINES AGAINST SARS-COV-2
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
US20230125469A1 (en) 2021-07-14 2023-04-27 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
US20230330254A1 (en) 2022-03-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof
WO2023180533A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024026470A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.S. LEE et al, "Transcriptional Regulation of two Genes Specifically induced by Glucose Starvation in a Hamster Mutant Fibroblast Cell Line", Volume 258, Number 1, pages 597-603, published 10 January 1983, by the American Society of Biological Chemists, Inc., Waverly Press (Baltimore, MD, USA), see Entire Document. *
A.Y. LIN et al, "A Calcium Ionophore-Inducible Cellular Promoter is Highly Active and has Enhancer like Properties", Molecular and Cellular Biology, Volume 6, Number 4, pages 1235-1243, published April 1986, by the American Society for Microbiology (Washington, D.C., USA). see Entire Document. *
J.G. IZANT et al, "Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA", Science, Volume 229, pages 345-352, published July 1985, by the American Association for the Advancement of Science (Washington, D.C., USA). see Entire Document. *
J.J. TOOLE et al, "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor", Nature, Volume 312, pages 342-347, published 22 November 1984, by MacMILLIAN Journals LTD (London, UK). see especially pages 342, 343, 345, and 346. *
J.W. ATTENELLO et al, "Regulation of a Hybrid Gene by Glucose and Temperature in Hamster Fibroblasts", Science, Volume 226, pages 187-190, published October 1984, by the American Association for the Advancement of Science (Washington, D.C., USA), see Entire Document. *
S.C. CHANG et al, "Rat Gene Encoding the 78-kDA Glucose-Regulated Protein GRP78: Its Regulatory Sequences and the Effect of Protein Glycosylation on its Expression", Proceedings of the National Academy of Sciences USA, Volume 84, pages 680-684, published February 1987 by the National Academy of Sciences of the United States of America (Washington, D.C., USA). see especially Paragraph Bridging pages 680-681 Confirming the Anthenticity of the Genomic Clone of Ref. (13) (VIZ. ATTENELLO et al, Science 226: 187 (1984) Cited Above). *
See also references of EP0289597A4 *

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5789203A (en) * 1986-01-27 1998-08-04 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US6228620B1 (en) 1986-01-27 2001-05-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
US5866327A (en) * 1990-10-19 1999-02-02 Board Of Trustees Of The University Of Illinois Association of kinensin with sensitivity to chemotherapeutic drugs
US5811234A (en) * 1990-10-19 1998-09-22 Board Of Trustees Of University Of Illinois Methods and applications for efficient genetic suppressor elements
WO1992007071A1 (en) * 1990-10-19 1992-04-30 The Board Of Trustees Of The University Of Illinois Methods and applications for efficient genetic suppressor elements
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
US6541603B1 (en) 1990-10-19 2003-04-01 The Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to platinum-based drugs
US6376241B1 (en) 1991-10-11 2002-04-23 Board Of Trustees Of The University Of Illinois Methods and applications for efficient genetic suppressor elements
WO1994011503A2 (en) 1992-11-13 1994-05-26 Genetics Institute, Inc. Chimeric factor viii
US6268134B1 (en) 1993-09-07 2001-07-31 Board Of Trustees Of University Of Il Method and applications for efficient genetic suppressor elements
WO1997020055A1 (en) * 1995-11-07 1997-06-05 Interpharm Laboratories Ltd. Use of anti-sense sequences to increase responsiveness to gene amplification
US6399377B1 (en) 1995-11-27 2002-06-04 Yves Mory Use of anti-sense sequences to increase responsiveness to gene amplification
US6838437B2 (en) 1996-04-24 2005-01-04 University Of Michigan Inactivation resistant factor VIII
EP2202242A1 (en) 1996-04-24 2010-06-30 The Regents of The University of Michigan Inactivation resistant factor VIII related applications
EP1754718A2 (en) 1996-04-24 2007-02-21 The Regents of The University of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7459534B2 (en) 1996-04-24 2008-12-02 The Regents Of The University Of Michigan Inactivation resistant factor VIII
US6683159B2 (en) 1998-03-12 2004-01-27 Genetics Institute, Llc Methods for producing factor VIII proteins
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2007509616A (en) * 2003-10-27 2007-04-19 ユニバーシティ オブ サウザーン カリフォルニア Methods and compositions for modulating apoptosis
JP2010233569A (en) * 2003-10-27 2010-10-21 Univ Of Southern California Method and composition for adjusting apoptosis
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP2520586A1 (en) 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
US9758776B2 (en) 2009-08-24 2017-09-12 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
US9376672B2 (en) 2009-08-24 2016-06-28 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
EP3326643A1 (en) 2009-12-06 2018-05-30 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US9050318B2 (en) 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
EP3906937A1 (en) 2009-12-06 2021-11-10 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US9241978B2 (en) 2009-12-06 2016-01-26 Biogen Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
US11266720B2 (en) 2009-12-06 2022-03-08 Bioverativ Therapeutics Inc. Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
US10010622B2 (en) 2011-07-08 2018-07-03 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
EP3513804A1 (en) 2011-07-08 2019-07-24 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10881742B2 (en) 2011-07-08 2021-01-05 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
US11747351B2 (en) 2011-07-25 2023-09-05 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EP3970737A1 (en) 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
US11286528B2 (en) 2012-01-12 2022-03-29 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
US10221455B2 (en) 2012-01-12 2019-03-05 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
EP3453402A1 (en) 2012-01-12 2019-03-13 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
EP3505179A1 (en) 2012-01-12 2019-07-03 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
US11685771B2 (en) 2012-02-15 2023-06-27 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
US10421798B2 (en) 2012-02-15 2019-09-24 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
EP4269431A1 (en) 2012-07-11 2023-11-01 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
US11091534B2 (en) 2012-07-11 2021-08-17 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3674410A1 (en) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US11372008B2 (en) 2012-07-25 2022-06-28 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
US10786554B2 (en) 2013-03-15 2020-09-29 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US9623088B2 (en) 2013-03-15 2017-04-18 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
EP3666283A1 (en) 2013-03-15 2020-06-17 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP4176894A1 (en) 2014-01-10 2023-05-10 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015106052A1 (en) 2014-01-10 2015-07-16 Biogen Ma Inc. Factor viii chimeric proteins and uses thereof
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Also Published As

Publication number Publication date
CA1297436C (en) 1992-03-17
EP0289597A4 (en) 1990-03-27
AU1100288A (en) 1988-06-01
JPH01501363A (en) 1989-05-18
US4912040A (en) 1990-03-27
EP0289597A1 (en) 1988-11-09
ES2013324A6 (en) 1990-05-01
DE3789017D1 (en) 1994-03-17
EP0289597B1 (en) 1994-02-02
KR890700164A (en) 1989-03-10

Similar Documents

Publication Publication Date Title
EP0289597B1 (en) Eucaryotic expression system
CA2368797C (en) Cell culture process
Pannekoek et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.
US5789203A (en) Protein complexes having factor VIII:C activity and production thereof
US5451521A (en) Procoagulant proteins
US5004803A (en) Production of procoagulant proteins
EP0506757B2 (en) A recombinant human factor viii derivative
US5422260A (en) Human factor VIII:c muteins
Pittman et al. Role of the B domain for factor VIII and factor V expression and function
EP0500734B1 (en) Protein complexes having factor viii:c activity and production thereof
Grinnell et al. Trans–Activated Expression of Fully Gamma–Carboxylated Recombinant Human Protein C, an Antithrombotic Factor
JPH0788399B2 (en) Novel procoagulant protein
US5071972A (en) DNA sequences encoding novel thrombolytic proteins
US20060122376A1 (en) Protein complexes having factor VIII:C activity and production thereof
EP0297066B1 (en) Novel fibrinolytic enzymes
Dingermann et al. Expression of human antithrombin III in the cellular slime mould Dictyostelium discoideum
US5002887A (en) Truncated thrombolytic proteins
US5002874A (en) Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
JPH1052266A (en) Production of tissue plasminogen activation factor
US5149635A (en) Messenger RNA stabilization in animal cells
WO1989000191A1 (en) Novel thrombolytic proteins
EP0275856A1 (en) New plasminogen activators
EP0480923B1 (en) Method of producing proteins with fviii activity and/or fviii derivatives
US5610033A (en) Method of producing proteins with FVIII activity and/or FVIII derivatives
CA2095635A1 (en) Chinese hamster ovary cell retrovirus-like c particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988900621

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988900621

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988900621

Country of ref document: EP